Compounds > phytoestrogens
Page last updated: 2024-08-03 20:22:45

phytoestrogens

Description

Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS. [MeSH]

Cross-References

ID SourceID
PubMed CID56842207
MeSH IDM0068568

Synonyms (2)

Synonym
phytoestrogens
D048789000

Research

Studies (3,605)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (0.75)18.7374
1990's259 (7.18)18.2507
2000's1649 (45.74)29.6817
2010's1371 (38.03)24.3611
2020's299 (8.29)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials258 (6.80%)5.53%
Reviews844 (22.25%)6.00%
Case Studies23 (0.61%)4.05%
Observational4 (0.11%)0.25%
Other2,665 (70.24%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
gamma-aminobutyric acid
8
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule		2003201715.1low000620
5-hydroxytryptophan
1
hydroxytryptophanhuman metabolite;
neurotransmitter		2011201113.0low000010
agmatine
1
guanidines;
primary amino compound		Escherichia coli metabolite;
mouse metabolite		2002200222.0low000100
allantoin
2
imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary		201820195.5low000020
betaine
2
amino-acid betaine;
glycine derivative		fundamental metabolite1998202214.0low101001
1-butanol
1
alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent		202020204.0low000010
methane
1
alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas		2007200717.0low000100
chlordecone
1
cyclic ketone;
organochlorine compound		insecticide;
persistent organic pollutant		2008200816.0low000100
choline
3
cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite		200920227.7low100111
chlorine
3
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		1997201815.0low101020
hydrochloric acid
1
chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite202120213.0low000001
coumarin
3
coumarinsfluorescent dye;
human metabolite;
plant metabolite		1995202017.0low001110
phloroglucinol
1
benzenetriol;
phenolic donor		algal metabolite201520159.0low000010
n(g),n(g')-dimethyl-l-arginine
1
alpha-amino acid2010201014.0low100100
1-aminocyclopropane-1-carboxylic acid
1
amino acid zwitterion;
monocarboxylic acid;
non-proteinogenic alpha-amino acid		ethylene releasers;
plant metabolite		202320231.0low000001
dibenzofuran
1
dibenzofurans;
mancude organic heterotricyclic parent;
polycyclic heteroarene		xenobiotic202220222.0low100001
creatine
1
glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical		201920195.0low000010
lactic acid
1
2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite		2013201311.0low000010
dimethyl sulfoxide
2
sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger		2002201714.5low000110
ethanolamine
1
ethanolamines;
primary alcohol;
primary amine		Escherichia coli metabolite;
human metabolite;
mouse metabolite		201720177.0low000010
hexachlorocyclohexane
1
chlorocyclohexane2002200222.0low000100
glycine
1
alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical		1999199925.0low001000
glycerol
1
alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent		2008200816.0low000100
hydrogen carbonate
1
carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2014201410.0low000010
dalteparin
1
2008200816.0low000100
iodine
2
diatomic iodinenutrient2001200620.5low000200
methanol
8
alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite		2000202213.4low001331
methanol
10
alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite		2000202214.3low001441
phytic acid
5
inositol phosphate2001202015.0low000320
melatonin
7
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		2002202214.1low100511
nickel
1
metal allergen;
nickel group element atom		epitope;
micronutrient		2009200915.0low000100
niacinamide
1
pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor		201520159.0low000010
nitrates
5
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		2003201414.8low100320
nitrites
7
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite2001201912.4low000250
palmitic acid
1
long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite		201620168.0low000010
pentachlorophenol
1
aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes		human xenobiotic metabolite2004200420.0low000100
phenol
3
phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite		2003201613.0low000120
phosphoenolpyruvate
1
carboxyalkyl phosphate;
monocarboxylic acid		fundamental metabolite201720177.0low000010
phthalic acid
7
benzenedicarboxylic acidhuman xenobiotic metabolite2000201616.9low001420
pyrazole
1
pyrazole2011201113.0low000010
taurine
1
amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite		201920195.0low000010
uric acid
3
uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite		201020228.7low100111
huperzine a
1
quinolone2003200321.0low000100
1-(3-chlorophenyl)biguanide
1
biguanides;
monochlorobenzenes		201720177.0low000010
1-anilino-8-naphthalenesulfonate
1
aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe201920195.0low000010
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
2
methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin2003200918.0low000200
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
1
imidazopyridine;
primary amino compound		carcinogenic agent;
mutagen		1999199925.0low001000
3-nitropropionic acid
1
C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin		201620168.0low000010
4-nonylphenol
4
phenolsenvironmental contaminant2002201017.2low000400
acetaminophen
1
acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2003200321.0low000100
alendronate
3
1,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor		2002201814.7low000210
aminoglutethimide
1
dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		1996199628.0low001000
anastrozole
2
nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		2005201812.5low000110
aspirin
1
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		201520159.0low000010
atrazine
2
chloro-1,3,5-triazine;
diamino-1,3,5-triazine		environmental contaminant;
herbicide;
xenobiotic		2003202211.5low000101
bay-k-8644
3
(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester		2002200919.7low000300
benzo(a)pyrene
1
ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite		202220222.0low100001
5-methoxypsoralen
1
5-methoxyfurocoumarin;
organic heterotricyclic compound;
psoralens		hepatoprotective agent;
plant metabolite		202120213.0low000001
beta-naphthoflavone
2
extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist201420169.0low000020
caffeine
6
purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic		2001201815.5low000510
verapamil
1
aromatic ether;
nitrile;
polyether;
tertiary amino compound		2007200717.0low000100
camphor, (+-)-isomer
1
bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite2003200321.0low000100
cetyltrimethylammonium ion
1
quaternary ammonium ion2010201014.0low000100
ciprofloxacin
1
aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic		2010201014.0low000100
citalopram
1
2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound		2003200321.0low000100
clonidine
10
clonidine;
imidazoline		2002201915.1low000730
diazepam
1
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic		2009200915.0low000100
dibutyl phthalate
1
diester;
phthalate ester		EC 3.2.1.20 (alpha-glucosidase) inhibitor;
environmental contaminant;
metabolite;
plasticiser;
teratogenic agent		2003200321.0low000100
diclofenac
1
amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		202220222.0low100001
ddt
10
benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant		1997201020.8low003700
3,3'-diindolylmethane
3
indolesantineoplastic agent;
P450 inhibitor		2007201710.7low000120
valproic acid
1
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		2007200717.0low000100
donepezil
1
aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent		201520159.0low000010
econazole
1
dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes		2009200915.0low000100
emodin
3
trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor		200120229.0low100102
erythrosine
1
1999199925.0low001000
ether
1
ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant		2004200420.0low000100
ethoxyresorufin
1
phenoxazine2011201113.0low000010
ethylenediamine
1
alkane-alpha,omega-diamineGABA agonist201520159.0low000010
etidronate
2
1,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator		1999200920.0low101100
fluoxetine
1
(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound		2010201014.0low000100
flutamide
3
(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent		2001201318.3low000210
gabapentin
10
gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic		2003201913.1low000640
gentamicin
2
201020199.5low000110
glyburide
1
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		201620168.0low000010
glyphosate
1
glycine derivative;
phosphonic acid		agrochemical;
EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor;
herbicide		1999199925.0low001000
gossypol
1
2008200816.0low000100
guaifenesin
1
methoxybenzenes202220222.0low000001
indole-3-carbinol
3
indolyl alcoholantineoplastic agent;
plant metabolite		1999200721.0low001200
ipriflavone
6
aromatic ether;
isoflavones		bone density conservation agent1997201020.5low202400
2-propanol
1
secondary alcohol;
secondary fatty alcohol		protic solvent2005200519.0low000100
isoproterenol
3
catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent		2001201614.3low000120
ketamine
1
cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic		202120213.0low000001
ketoprofen
1
benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic		202220222.0low100001
mimosine
2
alpha-amino acid2003201614.5low000110
lavendustin a
1
aromatic amine2006200618.0low000100
letrozole
4
nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		201420216.5low000031
losartan
1
biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist		202220222.0low100001
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2
chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector		2008201015.0low000200
edaravone
1
pyrazoloneantioxidant;
radical scavenger		202220222.0low100001
mephenytoin
1
imidazolidine-2,4-dioneanticonvulsant202220222.0low100001
metformin
3
guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic		201020199.3low000120
methoxychlor
6
organochlorine insecticide2000200621.3low001500
methyl parathion
1
C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
antifungal agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
genotoxin		2004200420.0low000100
metronidazole
1
C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic		2010201014.0low000100
mitoxantrone
2
dihydroxyanthraquinoneanalgesic;
antineoplastic agent		201420169.0low000020
nifedipine
1
C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent		2009200915.0low000100
nisoxetine
1
aromatic ether;
secondary amino compound		adrenergic uptake inhibitor;
antidepressant		2010201014.0low000100
nitroglycerin
2
nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic		2004200718.5low000200
omeprazole
1
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		202220222.0low100001
oxidopamine
3
benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin		2008201015.0low000300
quinone
1
1,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite		2002200222.0low000100
pd 98059
1
aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		2010201014.0low000100
phenobarbital
2
barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative		2003202211.5low100101
phloretin
2
dihydrochalconesantineoplastic agent;
plant metabolite		2013201410.5low000020
potassium chloride
5
inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer2006200916.6low000500
protoporphyrin ix
1
201620168.0low000010
resorcinol
1
benzenediol;
phenolic donor;
resorcinols		erythropoietin inhibitor;
sensitiser		2003200321.0low000100
rofecoxib
1
butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		2010201014.0low000100
saccharin
1
1,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic		2013201311.0low000010
safrole
1
benzodioxolesflavouring agent;
insecticide;
metabolite;
plant metabolite		201520159.0low000010
sodium fluoride
1
fluoride saltmutagen2009200915.0low000100
fluoroacetic acid
1
haloacetic acid;
organofluorine compound		EC 4.2.1.3 (aconitate hydratase) inhibitor1983198341.0low010000
risedronic acid
3
pyridines1999201516.3low201110
sulforaphane
1
isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite		1999199925.0low001000
sulpiride
1
benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist		2003200321.0low000100
triclosan
3
aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic		200620229.0low000111
trigonelline
2
alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite		200920209.5low000110
tyramine
1
monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter		2001200123.0low000100
corticosterone
13
11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		2003202211.0low000391
estriol
5
16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite		2006201513.6low000320
alloxan
1
pyrimidonehyperglycemic agent;
metabolite		2014201410.0low000010
thymidine
3
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite		2001200920.0low000300
hydroxyproline
4
4-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite		1998201319.0low101210
thyroxine
4
2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone		2008201114.2low100220
carbachol
3
ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic		2001201216.0low000120
norethindrone acetate
2
3-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive		2005201016.5low200200
spironolactone
1
3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic		2012201212.0low000010
aldosterone
2
11beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite		2004202012.0low000110
estrone
22
17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite		1995202312.1low4021064
androsterone
1
17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone		2002200222.0low000100
dehydroepiandrosterone
4
17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite		1994202015.8low002020
pentylenetetrazole
3
organic heterobicyclic compound;
organonitrogen heterocyclic compound		201220188.3low000030
triiodothyronine
4
2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone		2008201114.8low000310
biguanides
1
guanidines201720177.0low000010
carbon tetrachloride
2
chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant		2005202111.0low000101
serine
2
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2009201213.5low000110
desoxycorticosterone acetate
1
corticosteroid hormone201620168.0low000010
4-nitroquinoline-1-oxide
1
C-nitro compound;
quinoline N-oxide		carcinogenic agent2007200717.0low000100
lysine
1
aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2013201311.0low000010
physostigmine
1
carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic		2003200321.0low000100
sucrose
1
glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent		201720177.0low000010
ethinyl estradiol
19
17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen1993201816.7low1021250
testosterone propionate
1
steroid ester2003200321.0low000100
9,10-dimethyl-1,2-benzanthracene
10
ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent2001201715.4low000730
apomorphine
3
aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug		2007201414.3low000210
kanamycin a
1
kanamycinsbacterial metabolite201620168.0low000010
bromodeoxyuridine
1
pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent		2005200519.0low000100
galactose
1
D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite		2007200717.0low000100
carbostyril
1
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite2014201410.0low000010
phenylephrine
3
phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent		2009201412.7low000120
phenylethyl alcohol
1
benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite		2014201410.0low000010
tyrosine
4
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		2001201415.8low000220
phlorhizin
2
aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite		1997201020.5low001100
leucine
1
amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		202220222.0low100001
androstenedione
7
17-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite		2001201417.0low100520
methionine
4
aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical		200920237.8low100112
phenylalanine
1
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		202220222.0low000001
colchicine
1
alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen		202220222.0low100001
cycloheximide
2
antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor		2004201017.0low000200
ficusin
1
psoralensplant metabolite2010201014.0low000100
egtazic acid
2
diether;
tertiary amino compound;
tetracarboxylic acid		chelator1999200721.0low001100
norethindrone
2
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive		2005201016.5low200200
mannitol
1
mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent		2013201311.0low000010
medroxyprogesterone acetate
4
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive		1996200722.0low101300
mestranol
1
17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen		2005200519.0low000100
tryptophan
1
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		201820186.0low000010
arginine
5
arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical		2004202214.6low200401
methylamine
1
methylamines;
one-carbon compound;
primary aliphatic amine		mouse metabolite1998199826.0low001000
propane
1
alkane;
gas molecular entity		food propellant2001200123.0low000100
methylene chloride
2
chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant		201320198.0low000020
2-bromopropane
1
2001200123.0low000100
trimethylchlorosilane
1
silyl chloridechromatographic reagent2009200915.0low000100
tribromoethanol
1
alcohol;
organobromine compound		2008200816.0low000100
tert-butylhydroperoxide
3
alkyl hydroperoxideantibacterial agent;
oxidising agent		1999200918.7low001200
trifluoroacetic acid
2
fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent		1995201718.0low001010
phencyclidine
1
benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug		202220222.0low100001
bisphenol a
55
bisphenolendocrine disruptor;
environmental contaminant;
xenobiotic;
xenoestrogen		1998202213.1low10321283
9,10-phenanthrenequinone
1
phenanthrenes2006200618.0low000100
2,6-dihydroxyanthraquinone
1
dihydroxyanthraquinoneantimutagen;
plant metabolite		2001200123.0low000100
quinoxalines
1
mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene		202220222.0low100001
diphenyl
1
aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative		2011201113.0low000010
4-biphenylamine
1
aminobiphenylcarcinogenic agent1999199925.0low001000
xanthenes
1
xanthene201520159.0low000010
1-phenylpropanol
1
organic molecular entity202020204.0low000010
propylparaben
1
benzoate ester;
paraben;
phenols		antifungal agent;
antimicrobial agent		2006200618.0low000100
1,2-dibromo-3-chloropropane
1
organochlorine compound2001200123.0low000100
4-butyrolactone
93
butan-4-olidemetabolite;
neurotoxin		1986202115.5low511145342
furfuryl alcohol
1
furans;
primary alcohol		Maillard reaction product2012201212.0low000010
diphenylmethane
3
diarylmethane2001200521.0low000300
ethyl bromoacetate
1
202220222.0low100001
propionitrile
1
aliphatic nitrile;
volatile organic compound		polar aprotic solvent2011201113.0low000010
2-methylpentane
1
alkane2014201410.0low000010
cyclohexanol
1
cyclohexanols;
secondary alcohol		solvent2002200222.0low000100
pyrroles
1
pyrrole;
secondary amine		201520159.0low000010
thiophenes
2
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent2001201416.5low000110
n-hexane
1
alkane;
volatile organic compound		neurotoxin;
non-polar solvent		2014201410.0low000010
heptanol
4
heptanol;
primary alcohol		flavouring agent;
fragrance;
gap junctional intercellular communication inhibitor;
plant metabolite		2012201610.5low000040
carbitol
1
diether;
glycol ether;
hydroxypolyether;
primary alcohol		protic solvent201820186.0low000010
estradiol dipropionate
1
steroid ester201620168.0low000010
diethylhexyl phthalate
4
diester;
phthalate ester		androstane receptor agonist;
apoptosis inhibitor;
plasticiser		201320208.5low000040
benzoin
2
benzoins;
secondary alpha-hydroxy ketone		EC 3.1.1.1 (carboxylesterase) inhibitor2004200718.5low000200
2-naphthol
2
naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger		200720229.5low100101
4-tert-octylphenol
1
alkylbenzene2000200024.0low001000
citronellol
1
monoterpenoidplant metabolite202220222.0low100001
ethyl acetate
4
acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite		2004202012.2low000220
pregnenolone
1
20-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite		2013201311.0low000010
potassium cyanide
1
cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin		202220222.0low100001
quinestrol
2
17-hydroxy steroid;
terminal acetylenic compound		xenoestrogen2010201213.0low000110
catechin
10
catechinantioxidant;
plant metabolite		1999202015.3low001540
cyclopentane
1
cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent202220222.0low100001
isoxazoles
1
isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		202220222.0low100001
oxazoles
6
1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2007201812.5low000240
thiazoles
8
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2002201415.8low000620
ethynodiol diacetate
1
steroid ester;
terminal acetylenic compound		contraceptive drug;
estrogen receptor modulator;
synthetic oral contraceptive		2005200519.0low000100
hydrazine
2
azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor2004200818.0low000200
monocrotaline
1
pyrrolizidine alkaloid201720177.0low000010
azacitidine
3
N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent2008201511.7low000120
galantamine
1
benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite		2003200321.0low000100
methysergide
1
ergoline alkaloid2003200321.0low000100
cuprizone
1
organonitrogen compound;
organooxygen compound		201920195.0low000010
citrulline
2
amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite		2005200618.5low000200
cyproterone acetate
1
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin		2009200915.0low000100
deoxybenzoin
2
2004200718.5medium000200
beta-erythroidine
1
delta-lactone;
indole alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		muscle relaxant;
plant metabolite		2014201410.0low000010
fusarium
3
200320228.7low000102
aloe emodin
1
aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite		2001200123.0low000100
imperatorin
1
psoralensEC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite		201620168.0low000010
osthol
1
botanical anti-fungal agent;
coumarins		metabolite201620168.0low000010
flavanone
1
flavanones2006200618.0low000100
kainic acid
1
dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist		2006200618.0low000100
butenolide
1
butenolide2010201014.0low000100
4-hydroxyphenylethanol
1
phenolsanti-arrhythmia drug;
antioxidant;
cardiovascular drug;
fungal metabolite;
geroprotector;
plant metabolite;
protective agent		2014201410.0low000010
alpha-aminopyridine
1
202220222.0low100001
oleanolic acid
1
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite2002200222.0low000100
podophyllotoxin
1
furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator		2008200816.0low000100
hesperidin
2
3'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen200820229.0low100101
medroxyprogesterone
2
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive		2004200917.5low100200
dihydrotestosterone
15
17beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite		1997201617.9low202940
angelicin
1
furanocoumarin2010201014.0low000100
flavone
3
flavonesmetabolite;
nematicide		2003201315.3low000210
copper gluconate
1
organic molecular entity201520159.0low100010
malondialdehyde
18
dialdehydebiomarker2004202113.0low200981
trinitrobenzenesulfonic acid
1
arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent		2008200816.0low000100
malachite green
1
organic chloride saltantibacterial agent;
antifungal drug;
carcinogenic agent;
environmental contaminant;
fluorochrome;
histological dye;
teratogenic agent		2008200816.0low000100
3-hydroxyflavone
5
flavonols;
monohydroxyflavone		2007202212.0low100311
diphenylamine
1
aromatic amine;
bridged diphenyl fungicide;
secondary amino compound		antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger		202220222.0low100001
alpha-naphthoflavone
1
extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor		2009200915.0low000100
acetylcysteine
1
acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary		2002200222.0low000100
c.i. 42510
1
2008200816.0low000100
dehydroepiandrosterone sulfate
5
17-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite		1999200919.8low401400
methylnitrosourea
4
N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent		2003201616.0low000310
o,p'-ddt
2
diarylmethane1997200921.0low001100
levonorgestrel
1
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive		2012201212.0low000010
dimethyl phosphate
1
dialkyl phosphate2013201311.0low000010
boldenone
1
17beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
anabolic androgenic steroid		2005200519.0low000100
d-alpha tocopherol
24
alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite		2000201716.4low4011580
tocopherols
4
2002202211.8low000211
4-octylphenol
1
phenolsmetabolite;
surfactant;
xenoestrogen		2008200816.0low000100
diallyl disulfide
3
organic disulfideantifungal agent;
antineoplastic agent;
plant metabolite		2003201017.3low000300
fluorescein
1
2-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium		2009200915.0low000100
glycidyl trimethylammonium chloride
1
201520159.0low000010
sabinene
2
thujeneplant metabolite2008201313.5low000110
dithiothreitol
1
1,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent		202220222.0low100001
dideoxyadenosine
1
adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor		2006200618.0low000100
iodinated glycerol
9
dioxolane1965202218.8low010341
limonene
1
cycloalkene;
p-menthadiene		human metabolite2010201014.0low000100
manganese
1
elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient		201820186.0low000010
mercury
1
elemental mercury;
zinc group element atom		neurotoxin202220222.0low000001
ruthenium
1
iron group element atom;
platinum group metal atom		202220222.0low100001
silver
1
copper group element atom;
elemental silver		Escherichia coli metabolite202220222.0low100001
titanium
1
titanium group element atom202220222.0low100001
europium
2
f-block element atom;
lanthanoid atom		1998200025.0low002000
gold
1
copper group element atom;
elemental gold		201720177.0low000010
camptothecin
1
delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite		202220222.0low100001
ferric chloride
1
iron coordination entityastringent;
Lewis acid		1997199727.0low001000
tricalcium phosphate
1
calcium phosphate2013201311.0low000010
deuterium
3
dihydrogen1995200423.7low001200
vasotocin
1
2005200519.0low000100
ozone
1
elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer		202220222.0low100001
rhamnose
1
L-rhamnose201720177.0low000010
cycasin
1
201520159.0low000010
tetradecanoylphorbol acetate
6
acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator		2005201417.0low000510
fluorides
1
halide anion;
monoatomic fluorine		1995199529.0low001000
daunorubicin
2
aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite		2008200915.5low000200
phosphotyrosine
1
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine		Escherichia coli metabolite;
immunogen		2007200717.0low000100
phenyl acetate
7
benzenes;
phenyl acetates		2003202213.3low100421
cetylpyridinium chloride anhydrous
6
chloride salt;
organic chloride salt		antiseptic drug;
surfactant		1999201417.0low101410
4-ethylphenol
5
phenolsfungal xenobiotic metabolite2006201715.8low000410
pregnanolone
1
3-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative		201920195.0low000010
4-methoxyamphetamine
1
202220222.0low100001
dihydro-beta-erythroidine
1
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound		nicotinic antagonist2014201410.0low000010
androstane-3,17-diol
3
17-hydroxy steroid;
3-hydroxy steroid;
androstanoid		2002200619.7low100300
glutamic acid
3
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		2002200917.7low000300
azoxymethane
1
1999199925.0low001000
tramadol
1
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor		202220222.0low100001
gallium citrate
1
202220222.0low100001
procymidone
1
2005200519.0low000100
paclitaxel
1
taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent		2007200717.0low000100
1-methyl-4-phenylpyridinium
1
pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin		2002200222.0low000100
vinclozolin
6
dicarboximide;
dichlorobenzene;
olefinic compound;
oxazolidinone		2007201812.5low000240
ng-nitroarginine methyl ester
4
alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor2002201016.8low000400
decamethrin
1
aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound		agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide		2007200717.0low000100
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
1
chromanol;
monocarboxylic acid;
phenols		antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor		1998199826.0low001000
epirubicin
1
aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor		2013201311.0low000010
colforsin
3
acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist		2000201814.0low001020
agreal
1
sulfonamide2003200321.0low000100
lovastatin
1
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug		2011201113.0low000010
raloxifene hydrochloride
27
hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator		1999202118.2low1051651
itraconazole
1
aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor		202220222.0low100001
fura-2
3
2003200918.0low000300
finasteride
1
3-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor		202120213.0low000001
mibefradil
1
tetralinsT-type calcium channel blocker2007200717.0low000100
lamivudine
1
monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug		202220222.0low100001
emtricitabine
1
monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor		202220222.0low100001
adenosine
1
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		2007200717.0low000100
vanadates
3
trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor		2007201513.3low000210
venlafaxine hydrochloride
1
hydrochloride2002200222.0low000100
trazodone hydrochloride
6
hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor		1995201919.8low303210
efavirenz
1
acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor		202220222.0low100001
glucose, (beta-d)-isomer
20
D-glucopyranoseepitope;
mouse metabolite		2005202112.2low1001091
2',7'-dichlorofluorescein
1
2-benzofuransfluorochrome1999199925.0low001000
thiazolyl blue
6
organic bromide saltcolorimetric reagent;
dye		2002201017.5low000600
arctigenin
6
lignan201320227.0low000051
allicin
2
botanical anti-fungal agent;
sulfoxide		antibacterial agent2010201312.5low000110
methylthymidine
1
2002200222.0low000100
epigallocatechin gallate
5
flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite		1999201818.0low001310
n,n-bis(trimethylsilyl)-2,2,2-trifluoroacetamide
1
2009200915.0low000100
glutathione disulfide
2
glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite		2010201312.5low000110
secoisolariciresinol
22
secoisolariciresinolantidepressant;
phytoestrogen;
plant metabolite		1995202311.6medium1024151
2-methoxyestradiol
1
17beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite		2007200717.0low000100
estradiol-3-sulfate
1
17beta-hydroxy steroid;
steroid sulfate		mammalian metabolite1993199331.0low001000
estradiol 3,17-disulfate
1
steroid sulfate2001200123.0medium000100
1,7-phenanthroline
2
phenanthroline2008201114.5low000110
triazoles
3
1,2,3-triazole2005201712.0low000120
lupulon
1
beta-bitter acidangiogenesis inhibitor;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer		2014201410.0low000010
pinocembrin
1
(2S)-flavan-4-one;
dihydroxyflavanone		antineoplastic agent;
antioxidant;
metabolite;
neuroprotective agent;
vasodilator agent		2008200816.0low000100
isocoumarins
1
isocoumarins2005200519.0low000100
sesamol
1
benzodioxoles2009200915.0low000100
fluorodeoxyglucose f18
1
2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose		202220222.0low100001
uk 68798
1
aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker		2001200123.0low000100
masoprocol
3
nordihydroguaiaretic acidantineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite		1991199928.7low003000
tocophersolan
1
tocol2013201311.0low000010
hesperetin
1
3'-hydroxyflavanones;
4'-methoxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone		antineoplastic agent;
antioxidant;
plant metabolite		2008200816.0low000100
sesamin
1
benzodioxoles;
furofuran;
lignan		antineoplastic agent;
neuroprotective agent;
plant metabolite		2009200915.0low000100
rubrofusarin
1
aromatic ether;
benzochromenone;
phenols;
polyketide		biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
fungal metabolite		2007200717.0low000100
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane
1
bisphenol2002200222.0low000100
rosiglitazone
1
aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug		2009200915.0low000100
bisecurin i
1
2005200519.0low000100
acetaminophen sulfate ester
1
acetamides;
aryl sulfate		drug metabolite2003200321.0low000100
o-desmethylangolensin
21
stilbenoid1986202015.7high2128100
nicotine
2
3-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic		2006202210.0low100101
fibrinogen
4
iditolfungal metabolite2005201016.5low300400
aucubin
1
organic molecular entitymetabolite201720177.0low000010
equol
248
hydroxyisoflavans1984202314.0high374219910915
homocysteine
5
amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite		2005201415.2low100320
gamma-tocopherol
1
tocopherol;
vitamin E		algal metabolite;
food antioxidant;
plant metabolite		2007200717.0low000100
indole-3-lactic acid
1
hydroxy monocarboxylic acid;
indol-3-yl carboxylic acid		human metabolite2011201113.0low000010
podocarpic acid
1
abietane diterpenoid2000200024.0low001000
2,5-dihydroxypyridine
1
dihydroxypyridinemouse metabolite202220222.0medium100001
diosgenin
4
3beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite		201120199.2low000040
phorbolol myristate acetate
2
2006200618.0low000200
syringaresinol
1
aromatic ether;
furofuran;
lignan;
polyether;
polyphenol		plant metabolite2013201311.0low000010
coumarin 6
1
7-aminocoumarinsfluorochrome2013201311.0low000010
sesamolin
1
benzodioxoles2009200915.0low000100
2,3-bis(4-hydroxyphenyl)-propionitrile
3
nitrile;
phenols		estrogen receptor agonist2009201114.0low000210
fulvestrant
58
17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist		1998202216.5low00438151
ici 164384
2
17beta-hydroxy steroid;
3-hydroxy steroid;
tertiary carboxamide		anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist		2000200024.0low002000
u 73122
2
aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor2005200618.5low000200
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole
1
ether;
imidazoles;
monomethoxybenzene		TRP channel blocker2009200915.0low000100
4-hydroxy-2',4',6'-trichlorobiphenyl
1
biphenyls;
trichlorobenzene		1999199925.0medium001000
pyridinoline
1
organonitrogen compound;
organooxygen compound		1998199826.0low001000
deoxypyridinoline
6
1998201915.3low301230
fura-2-am
1
2006200618.0low000100
indenestrol
1
1990199034.0low001000
procyanidin
2
proanthocyanidin2001200819.5low000200
pisatin
1
2011201113.0low000010
daidzin
15
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite2002201515.1low100960
proanthocyanidin
1
2001200123.0low000100
indenestrol b
1
1990199034.0medium001000
2,3-bis(3'-hydroxybenzyl)butyrolactone
93
lignan1986202315.3high511144334
indolo(3,2-b)carbazole
1
1994199430.0low001000
liquiritigenin
2
4',7-dihydroxyflavanonehormone agonist;
plant metabolite		2008201313.5low000110
tanshinone
2
abietane diterpenoidanticoronaviral agent2011201411.5low000020
soyasapogenol b
1
pentacyclic triterpenoid2002200222.0low000100
paspaline
1
organic heterotricyclic compound;
organooxygen compound		201520159.0low000010
matairesinol
6
gamma-lactone;
lignan;
polyphenol		angiogenesis inhibitor;
anti-asthmatic agent;
phytoestrogen;
plant metabolite		2000201413.5low001140
cucurbitacins
1
11-oxo steroid2001200123.0low000100
tris(2-carboxyethyl)phosphine
1
phosphine derivative;
tricarboxylic acid		reducing agent202220222.0low100001
293b cpd
1
1-benzopyran2001200123.0low000100
alliin
1
alpha-amino acid2013201311.0low000010
1-(4-methoxyphenyl)pyridinium
1
2003200321.0low000100
astragaloside a
1
2009200915.0low000100
2,3-bis(3'-hydroxybenzyl)butane-1,4-diol
38
lignan1986202316.5high41617122
n,n-dimethylarginine
1
dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor2010201014.0low100100
rmi 12330a
1
2012201212.0low000010
glabridin
5
hydroxyisoflavansantiplasmodial drug2001201515.4low000230
5,6,11,12,17,18-hexahydrocyclononatriindole
1
2003200321.0medium000100
lavendustin c6
2
2004201315.5high000110
methotrexate
1
dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent		201520159.0low000010
omega-n-methylarginine
1
amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		2001200123.0low100100
abiraterone
1
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor		202120213.0low000001
carbapenems
1
202220222.0low100001
beta-lactams
1
beta-lactam antibiotic allergen;
beta-lactam		202220222.0low100001
proline
1
amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		202220222.0low100001
centchroman
1
201920195.0low000010
paclitaxel
3
(2S)-flavan-4-one;
4'-hydroxyflavanones;
trihydroxyflavanone		T-type calcium channel blocker2010201511.0medium000120
hydroxyl radical
5
oxygen hydride;
oxygen radical;
reactive oxygen species		1999202211.4low101031
singlet oxygen
2
chalcogen;
monoatomic oxygen;
nonmetal atom		macronutrient201220227.0low100011
peroxymonosulfate
1
sulfur oxide;
sulfur oxoanion		202220222.0low100001
cryptotanshinone
1
abietane diterpenoidanticoronaviral agent201620168.0low000010
isoflavanone
5
isoflavanones2001201717.6low100410
glyceollin
3
organic heteropentacyclic compound2009201710.0low000120
tartrazine
1
202120213.0low000001
mirestrol
15
organic heterotricyclic compound;
organooxygen compound		201120238.1high0000132
n,n'-bis(salicylideneamino)ethane-manganese(ii)
1
2014201410.0low000010
angiotensin ii
5
amino acid zwitterion;
angiotensin II		human metabolite2005201914.4low000410
campesterol
2
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C28-steroid;
phytosterols		mouse metabolite1999201716.0low001010
lignin
9
1991201523.2low005220
sb 203580
3
imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent		2007201015.7low000300
dihydrodaidzein
6
hydroxyisoflavanonemetabolite2004201616.0medium000510
ly 353381
1
2001200123.0low000100
medioresinol
1
dimethoxybenzene;
furofuran;
lignan;
polyphenol		plant metabolite2013201311.0low000010
scutellarin
1
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor		2009200915.0low000100
glycitin
5
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
methoxyisoflavone;
monosaccharide derivative		plant metabolite2002202014.0medium100320
difructose anhydride iii
1
sugar dianhydride2006200618.0low000100
sorafenib
1
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor		201520159.0low000010
phenoxodiol
2
2006201712.5low000110
estradiol 3-benzoate
9
17beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen		2001201116.6low000810
equilin
2
17-oxo steroid;
3-hydroxy steroid		1990200427.0low001100
adrenosterone
1
11-oxo steroid;
17-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
human urinary metabolite;
marine metabolite		2009200915.0low000100
3-nitrotyrosine
1
2-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid		2014201410.0low000010
benzofurans
2
200720229.5low100101
lupeol
1
pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite		201920195.0low000010
lariciresinol
4
aromatic ether;
lignan;
oxolanes;
phenols;
primary alcohol		antifungal agent;
plant metabolite		2008201412.8low000220
medicarpin
1
medicarpinplant metabolite2000200024.0low001000
4-oxy-6-(4-oxybezoyloxy)dauc-8,9-en
7
2002202111.4medium000331
ritonavir
1
1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic		2010201014.0low000100
leupeptins
1
201720177.0low000010
glycogen
3
2002201911.3low000120
fibrin
1
peptide2014201410.0low000010
elastin
3
oligopeptide201420216.3low000021
raffinose
1
raffinose family oligosaccharide;
trisaccharide		mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		2004200420.0low000100
naringenin
20
(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite		1999202215.6low1021251
epiglucan
5
2008202011.0low100140
oxytocin
8
heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent		1997201318.1low101430
ouabain
1
11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite		2002200222.0low000100
puromycin
1
puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor		2004200420.0low000100
stachyose
1
raffinose family oligosaccharide;
tetrasaccharide		mouse metabolite;
plant metabolite		2004200420.0low000100
taxifolin
2
taxifolinmetabolite2009201810.5low000110
2-hydroxyestrone
1
2-hydroxy steroid;
catechols		human metabolite2006200618.0low000100
eriodictyol
1
3'-hydroxyflavanones;
tetrahydroxyflavanone		201520159.0low000010
pelargonidin
1
5-hydroxyanthocyanidinplant metabolite2007200717.0low000100
cellulase
1
cellotriose201720177.0low000010
ginsenoside re
1
12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
nephroprotective agent;
neuroprotective agent;
plant metabolite		2007200717.0low000100
ginsenoside rg1
3
12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		neuroprotective agent;
pro-angiogenic agent		2002201017.3low000300
naringin
1
(2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside		anti-inflammatory agent;
antineoplastic agent;
metabolite		2013201311.0low000010
cajanol
1
2013201311.0medium000010
gingerol
1
beta-hydroxy ketone;
guaiacols		antineoplastic agent;
plant metabolite		2005200519.0low000100
alpha bitter acid
1
aromatic ketone;
cyclic ketone;
diketone;
tertiary alpha-hydroxy ketone;
triol		antibacterial drug;
antioxidant;
cyclooxygenase 2 inhibitor;
metabolite		2014201410.0low000010
lignans
270
1986202315.5low73331269315
tibolone
11
17beta-hydroxy steroid;
terminal acetylenic compound		bone density conservation agent;
hormone agonist		2000201118.3low301910
betadex
5
cyclodextrin2009201711.6low000230
ergosterol
1
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite		1992199232.0low001000
trichostatin a
2
antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector		2003200818.5low000200
tretinoin
3
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		2000201616.7low001110
arachidonic acid
1
icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite		1991199133.0low001000
resveratrol
86
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		1997202214.4low50939344
retinol
6
retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite		2002201515.8low000420
ferulic acid
1
ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite		2014201410.0low000010
cocaine
1
benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		202120213.0low000001
cocaine
2
benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		2007202110.0low000101
thapsigargin
5
butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor		1999201618.2low001310
lycopene
5
acyclic caroteneantioxidant;
plant metabolite		2001200719.6low000500
adenosine-5'-(n-ethylcarboxamide)
1
adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		2012201212.0low000010
prostaglandin d2
1
prostaglandins Dhuman metabolite;
mouse metabolite		2009200915.0low000100
diethylstilbestrol
44
olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen		1993201419.7low0083330
h 89
1
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide2008200816.0low000100
afimoxifene
11
phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite		1997201419.1low002720
decitabine
1
2'-deoxyribonucleoside2008200816.0low000100
iridoids
1
202220222.0low100001
dactinomycin
2
actinomycinmutagen2005200618.5low000200
gamma-sitosterol
18
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite		1987202116.1low012681
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
1
amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor201720177.0low000010
tenofovir
1
nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor		202220222.0low100001
shikonin
1
hydroxy-1,4-naphthoquinone2011201113.0low000010
8-prenylnaringenin
50
(2S)-flavan-4-one;
4'-hydroxyflavanones;
trihydroxyflavanone		plant metabolite;
platelet aggregation inhibitor		1999202214.5high40327164
glabrene
3
isoflavonoid2001202115.7high000201
riboflavin
1
flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite		201820186.0low100010
8-isopentenylnaringenin
2
flavanones1998199826.0medium002000
isoxanthohumol
8
flavanones2007201413.4medium100440
bromochloroacetic acid
1
2-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound		2006200618.0low000100
anethole
1
anetholeflavouring agent2008200816.0low000100
geraniol
1
3,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol		allergen;
fragrance;
plant metabolite;
volatile oil component		202220222.0low100001
glycosides
9
2001202313.1low000351
isomethyleugenol
7
isomethyleugenol1995201417.0low001420
squalene
1
triterpenehuman metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		202220222.0low000001
stilbenes
87
stilbene1997202215.3low50944322
isoliquiritigenin
1
chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist		2013201311.0low000010
coumestan
8
coumestans;
delta-lactone		phytoestrogen;
plant metabolite		2006202010.6medium000260
xanthohumol
13
aromatic ether;
chalcones;
polyphenol		anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite		2001202113.7low200841
flavin-adenine dinucleotide
1
flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group		202220222.0low000001
gw9662
1
benzamides2012201212.0low000010
amygdalin
1
201520159.0low000010
sesquiterpenes
16
2002202112.7low000781
3,3',4,5'-tetrahydroxystilbene
2
catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor		2005201116.0low000110
3,6-dihydroxyflavone
1
2014201410.0low000010
caffeic acid
2
caffeic acidgeroprotector;
mouse metabolite		201520197.0low000020
cotinine
2
N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite		2013201510.0low000020
dieldrin
1
epoxide;
organochlorine compound;
organochlorine insecticide		carcinogenic agent;
xenobiotic		2000200024.0low001000
curcumin
8
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		2004201813.4low000440
curcumin
29
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		2004202211.4low1009182
capsaicin
4
capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker		2005201513.2low000220
enclomiphene
6
1999201317.8low401410
chlorogenic acid
1
cinnamate ester;
tannin		food component;
plant metabolite		2007200717.0low000100
D-fructopyranose
1
cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent201920195.0low000010
thioacetamide
1
thiocarboxamidehepatotoxic agent2014201410.0low000010
digoxin
2
cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope		2012201212.0low000020
tamoxifen
55
stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator		1993201819.5low001233100
nadp
1
202220222.0low100001
1,1-diphenyl-2-picrylhydrazyl
3
2004200818.3low000300
zeranol
24
macrolide1999202215.2low0011481
u 0126
3
aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent		2009201413.0low000210
droloxifene
1
stilbenoid1999199925.0low001000
androstane-3,17-diol glucuronide
2
steroid ester2005200618.5low100200
cystine
1
202220222.0low100001
cytellin
20
1987202116.7low013781
ginsenosides
6
2002201117.2low000510
ovalbumin
4
1998201318.8low002110
l 663536
1
aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist		2012201212.0low000010
flavan-3-ol
1
hydroxyflavonoid2013201311.0low000010
naphthoquinones
1
2011201113.0low000010
osteoprotegerin
16
long-chain fatty acid2005202311.2low1004111
rhodamine 123
1
organic cation;
xanthene dye		fluorochrome2009200915.0low000100
sphingosine
2
sphing-4-eninehuman metabolite;
mouse metabolite		201220179.5low000020
quercetin
57
7-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger		1997202114.8low00330222
dinoprostone
5
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		2007201612.2low000230
dinoprost
6
monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite		2000201317.3low101410
biochanin a
61
4'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		1987202215.0medium11725253
formononetin
66
4'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite		1988202112.8medium11522371
vitexin
1
C-glycosyl compound;
trihydroxyflavone		antineoplastic agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite;
platelet aggregation inhibitor		2003200321.0low000100
acacetin
1
dihydroxyflavone;
monomethoxyflavone		anticonvulsant;
plant metabolite		2008200816.0low000100
apigenin
23
trihydroxyflavoneantineoplastic agent;
metabolite		2000202314.6low0011192
apigenin
24
trihydroxyflavoneantineoplastic agent;
metabolite		1998202315.0low0021192
luteolin
8
3'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist		1998201912.5low001250
7,3'-dihydroxy-4'-methoxyisoflavone
11
4'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite		201120226.7low000074
calcitriol
8
D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical		2003201717.1low000620
calcitriol
7
D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical		2003201716.6low000520
vitamin k semiquinone radical
3
2003201517.0low000210
beta carotene
2
carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A		2000201715.5low101010
thromboxane a2
2
epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite2009201313.0low000110
apiin
1
beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone		EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
plant metabolite		2000200024.0low001000
stigmasterol
3
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols;
stigmastane sterol		plant metabolite1999201515.0low001020
cholecalciferol
5
D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite		2004201513.4low100230
rutin
3
disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite		200520228.3low100111
kaempferol
15
7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite		1997201715.1low001860
alpha-linolenic acid
3
linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical		201420178.7low000030
genistein
921
7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		1987202314.2high6036145236342
pulmicort
3
11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen		2012201510.3low000030
brassicasterol
1
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		algal metabolite;
animal metabolite;
biomarker;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
human metabolite;
marine metabolite;
plant metabolite;
sterol biosynthesis inhibitor		201720177.0low000010
genistin
19
7-hydroxyisoflavones 7-O-beta-D-glucoside1997201716.6low1031060
humulene
1
alpha-humulene2009200915.0low000100
oleuropein
1
beta-D-glucoside;
catechols;
diester;
methyl ester;
pyrans;
secoiridoid glycoside		anti-inflammatory agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
NF-kappaB inhibitor;
nutraceutical;
plant metabolite;
radical scavenger		202220222.0low100001
zearalenone
22
macrolide;
resorcinols		fungal metabolite;
mycoestrogen		1990202216.3low0031171
agathisflavone
1
biaryl;
biflavonoid;
hydroxyflavone		antineoplastic agent;
antiviral agent;
hepatoprotective agent;
metabolite		202020204.0low000010
chrysin
1
7-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite		1998199826.0low001000
diosmetin
1
3'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent		2009200915.0low000100
galangin
1
7-hydroxyflavonol;
trihydroxyflavone		antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite		2014201410.0low000010
hispidulin
1
monomethoxyflavone;
trihydroxyflavone		anti-inflammatory agent;
anticonvulsant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite		2014201410.0low000010
mangiferin
1
C-glycosyl compound;
xanthones		anti-inflammatory agent;
antioxidant;
hypoglycemic agent;
plant metabolite		201520159.0low000010
norathyriol
1
polyphenol;
xanthones		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite		201520159.0low000010
morusin
1
extended flavonoid;
trihydroxyflavone		antineoplastic agent;
plant metabolite		202220222.0low100001
myricetin
3
7-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite		2005201413.3low000120
wogonin
1
dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite		201620168.0low000010
coumestrol
112
coumestans;
delta-lactone;
polyphenol		anti-inflammatory agent;
antioxidant;
plant metabolite		1981202315.5high212041437
daidzein
469
7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite		1986202315.3high463402451729
trans-2,3',4,5'-tetrahydroxystilbene
1
stilbenoid201720177.0low000010
echinacoside
1
oligosaccharide2013201311.0low000010
irisolidone
1
4'-methoxyisoflavones2006200618.0low000100
rosmarinic acid
1
rosmarinic acidgeroprotector;
plant metabolite		202220222.0low100001
prunetin
3
7-methoxyisoflavones;
hydroxyisoflavone		anti-inflammatory agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite		2003201616.7low000210
tectoridin
3
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
methoxyisoflavone;
monosaccharide derivative		plant metabolite2006200916.3low000300
tectorigenin
7
7-hydroxyisoflavones;
methoxyisoflavone		anti-inflammatory agent;
plant metabolite		2004201317.0low000610
coenzyme q10
1
ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite		2006200618.0low000100
8-epi-prostaglandin f2alpha
2
F2-isoprostanebiomarker;
bronchoconstrictor agent;
vasoconstrictor agent		2000201019.0low101100
11-ketotestosterone
1
11-oxo steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
human metabolite;
marine xenobiotic metabolite		2011201113.0low000010
menatetrenone
1
menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent		2002200222.0low000100
ubiquinone 8
1
ubiquinonesbiomarker202220222.0low100001
menaquinone 6
1
2002200222.0low000100
sphingosine 1-phosphate
1
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent		201720177.0low000010
6,7,4'-trihydroxyisoflavone
1
7-hydroxyisoflavonesanti-inflammatory agent;
antimutagen;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite;
PPARalpha agonist;
PPARgamma agonist		2004200420.0low000100
fenretinide
1
monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant		2000200024.0low001000
lysophosphatidylcholines
1
1-O-acyl-sn-glycero-3-phosphocholine202220222.0low000001
broussonin a
1
2010201014.0medium000100
dehydroeffusol
1
201820186.0medium000010
glycitein
37
7-hydroxyisoflavone;
methoxyisoflavone		fungal metabolite;
phytoestrogen;
plant metabolite		1999202013.9high70319150
desmethylicaritin
2
2005201315.0medium000110
icaritin
3
2005201712.3low000120
icariin
6
flavonols;
glycosyloxyflavone		antioxidant;
bone density conservation agent;
EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
phytoestrogen		2005202311.2low000231
neobavaisoflavone
1
7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
plant metabolite;
platelet aggregation inhibitor		2010201014.0low000100
sophoricoside
1
acrovestone;
isoflavonoid		2010201014.0low000100
su 11248
1
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		201520159.0low000010
palbociclib
1
aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		201820186.0low000010
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
1
2007200717.0low000100
barium
2
alkaline earth metal atom;
elemental barium		1999200323.0low001100
aluminum
2
boron group element atom;
elemental aluminium;
metal atom		2002200819.0low000200
strontium
4
alkaline earth metal atom2003201910.0low000130
bismuth
1
metal atom;
pnictogen		202220222.0low100001
arsenic
1
metalloid atom;
pnictogen		micronutrient202220222.0low000001
gallium
1
boron group element atom202220222.0low100001
hinokiresinol
1
2000200024.0low001000
urolithin b
1
coumarins201620168.0low000010
puerarin
23
C-glycosyl compound;
isoflavonoid		2003201813.3low00011120
3,7-dihydroxyflavone
1
hydroxyflavan201720177.0low000010
ecdysterone
1
14alpha-hydroxy steroid;
20-hydroxy steroid;
22-hydroxy steroid;
25-hydroxy steroid;
2beta-hydroxy steroid;
3beta-sterol;
ecdysteroid;
phytoecdysteroid		animal metabolite;
plant metabolite		201520159.0low000010
cysteine
1
cysteiniumfundamental metabolite2013201311.0low000010
silicon
1
carbon group element atom;
metalloid atom;
nonmetal atom		201720177.0low000010
phosphorus
12
monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient2004202211.8low200561
boron
2
boron group element atom;
metalloid atom;
nonmetal atom		micronutrient2005202210.5low100101
irigenin
1
4'-methoxyisoflavones;
hydroxyisoflavone		plant metabolite2004200420.0low000100
bakuchiol
1
2011201113.0low000010
urolithin d
1
hydroxycoumarin201820186.0medium000010
pregabalin
3
gamma-amino acidanticonvulsant;
calcium channel blocker		201220197.3low000030
cladrin
1
201620168.0low000010
cinidon-ethyl
2
ethyl ester;
isoindoles;
monochlorobenzenes		herbicide201220189.0low000020
zearalenol
13
2001202215.1low000931
selenium
10
chalcogen;
nonmetal atom		micronutrient2000201517.3low003250
oxalates
3
1983202022.3low010110
dizocilpine maleate
2
maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		2005202210.5low100101
24,25-dihydroxyvitamin d 3
1
2004200420.0low000100
echinacin
1
2008200816.0low000100
alpha-cyperone
1
201920195.0low000010
beta-escin
13
1982202218.6low010921
4,5-diaminofluorescein diacetate
1
2009200915.0low000100
sq-23377
1
cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite		2009200915.0low000100
xct790
1
cinnamamides2014201410.0low000010
staurosporine
2
ammonium ion derivative2005200618.5low000200
hypericum
2
penicillanic acids2003200619.5low000200
mannich bases
1
202320231.0low000001
sin 1c
1
2007200717.0medium000100
cajanine
2
stilbenoid2007200916.0medium000200
mocetinostat
3
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		2008201512.0low000120
lipid a
1
dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite202220222.0low100001
ginsenoside rb1
2
ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger		2003201117.0low000110
thiocolchicoside
1
glycoside202220222.0low100001
secoisolariciresinol diglucoside
9
2005202311.0low100441
rucaparib
1
azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor		202220222.0low100001
hispolon
2
201720196.0low000020
artenimol
1
202220222.0low100001
licoflavone c
1
2004200420.0low000100
6-(1,1-dimethylallyl)naringenin
4
2002201019.2high000400
macelignan
1
lignan2009200915.0low000100
oxadiazoles
1
202220222.0low100001
hydroxymatairesinol
4
2001200719.2medium000400
lactulose
1
202220222.0low100001
dihydrogenistin
2
beta-D-glucoside;
hydroxyisoflavanone;
monosaccharide derivative		plant metabolite2003200420.5high000200
kwakhurin
2
7-hydroxyisoflavonesphytoestrogen2005202111.0medium000101
calcimycin
2
benzoxazole2007201413.5low000110
scopolamine hydrobromide
1
2010201014.0low000100
pituitrin
2
2003201714.0low000110
monascin
1
alpha,beta-unsaturated ketone;
gamma-lactone;
organic heterotricyclic compound;
polyketide		antilipemic drug;
antineoplastic agent;
fungal metabolite;
PPARgamma agonist		2011201113.0low000010
phytosterols
14
1992201917.4low003740
cyperotundone
1
sesquiterpenoid201920195.0medium000010
soyasapogenol a
1
pentacyclic triterpenoid2002200222.0low000100
acid phosphatase
5
2003201414.8low100320
ptaquiloside
1
201520159.0low000010
bavachin
2
2010201511.5low000110
ankaflavin
1
2011201113.0low000010
malonylgenistin
1
beta-D-glucoside;
glycosyloxyisoflavone;
hydroxyisoflavone;
malonate ester;
monosaccharide derivative		plant metabolite201920195.0low000010
nad
2
organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite		200920228.5low100101
mdv 3100
1
(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent		202120213.0low000001
cytochrome c-t
6
2007201812.3low000240
atrial natriuretic factor
1
polypeptide2003200321.0low000100
iturelix
1
2002200222.0low000100
glucagon
2
peptide hormone2005200618.5low000200
neuropeptide y
1
201520159.0low000010
iberiotoxin
1
2009200915.0low000100
tannins
2
2002202013.0low000110
antarelix
1
2001200123.0low000100
glucagon-like peptide 1
1
202220222.0low000001
c-peptide
1
2006200618.0low000100
natriuretic peptide, c-type
1
2003200321.0low000100
cellulose
2
glycoside201120227.5low200011
endothelin-1
6
2002201117.2low200510
phosphatidylcholines
2
1,2-diacyl-sn-glycero-3-phosphocholine2004202111.5low000101
chlorophyll a
1
chlorophyll;
methyl ester		cofactor201920195.0low000010
3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine
1
202220222.0low100001
sphingosine kinase
1
2012201212.0low000010
ubiquinone
2
2006202210.0low100101
pinoresinol
3
2010201611.0low000120
calpain
1
201520159.0low000010
chitosan
1
2011201113.0low000010
bucladesine
2
3',5'-cyclic purine nucleotide2000201815.0low001010
chiniofon
1
1999199925.0low001000
s-adenosylmethionine
1
organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		201520159.0low000010
corylifol a
1
2010201014.0low000100
cardiovascular agents
4
2002201318.2low000310
mannans
1
202220222.0low100001
glycolipids
1
2004200420.0low000100
piperidines
5
1999201518.8low002120
thymosin
1
1999199925.0low001000
interleukin-8
2
2006200916.5low000200
kakkalide
1
2006200618.0low000100
phillyrin
1
202120213.0low000001
deoxymiroestrol
10
200920219.5high000181
isoquercitrin
1
202020204.0low000010
heme
1
2009200915.0low000100
ascorbic acid
13
ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent		1997201718.5low202740
tetracycline
2
200820229.0low100101
roquinimex
1
aromatic amide1999199925.0low001000
warfarin
32
benzenes;
hydroxycoumarin;
methyl ketone		1981202312.7low0137192
teriflunomide
1
(trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide		drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor		202220222.0low100001
epidermal growth factor
7
1998201815.1low001330
bellergal
1
2003200321.0low000100
charybdotoxin
1
2009200915.0low000100
bismuth oxybromide
1
202220222.0low100001
transforming growth factor beta
5
201120236.0low000032
sybr green i
1
benzothiazolium ion;
cyanine dye;
quinolines;
tertiary amine		fluorescent dye2006200618.0low000100
pyrethrins
1
2007200717.0low000100
kiss1 protein, human
4
2009201412.2low000130
rome
1
2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-olEC 2.7.1.91 (sphingosine kinase) inhibitor201720177.0low100010
hirudin
1
202220222.0low100001
cyclin d1
6
2005202110.7low000231
caseins
11
1996201716.0low201550
ellagitannin
1
201620168.0low000010
phthalocyanine
1
phthalocyanines;
tetrapyrrole fundamental parent		201820186.0low000010
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
2
2005201315.0low000110
bassianolide
2
cyclodepsipeptide;
cyclooctadepsipeptide		antineoplastic agent;
fungal metabolite;
insecticide		2009201711.0low000110
adrenomedullin
1
2004200420.0low000100
vitamin b 12
2
201520197.0low000020
transforming growth factor alpha
2
1999201815.5low001010
lactoferrin
3
2002201414.0low000120
tetrahydrodaidzein
1
2006200618.0low000100
thromboplastin
1
2004200420.0low000100
amyloid beta-peptides
4
2011202010.0low000040
exudates
3
2007201612.0low000120
cyclic gmp
3
3',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		2003201016.7low100300
guanosine monophosphate
1
guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite		202120213.0low000001
folic acid
8
folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient		1995201715.6low002150
guanosine 5'-o-(3-thiotriphosphate)
1
nucleoside triphosphate analogue2008200816.0low000100
rifampin
1
cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor		2005200519.0low000100
allopurinol
1
nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger		2006200618.0low000100
sildenafil citrate
1
citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		2014201410.0low000010
fructooligosaccharide
2
oligosaccharide2006202210.0low000101
concanavalin a
1
2009200915.0low000100
metallothionein
2
2002200321.5low000200
phosphorus radioisotopes
1
1999199925.0low001000
leptin
14
2001202114.4low300941
phenanthrenes
4
2000201814.0low001120
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2019 Novel Coronavirus Disease0
4
202020222.8low200013
Abdominal Aortic Aneurysm0
1
2014201410.0low000010
Abdominal Cramps0
1
2001200123.0low000100
Abdominal Migraine0
2
2002200719.5low100200
Abdominal Obesity0
2
201420207.0low000020
Abnormalities, Autosome0
4
2003201017.5low100400
Abnormalities, Drug-Induced0
6
2004201616.2low000510
Abnormalities, Musculoskeletal0
1
2007200717.0low000100
Abortion, Spontaneous0
3
2004200818.3low100300
Abortion, Tubal0
3
2004200818.3low100300
Absence Seizure0
5
201220187.8low000050
Academic Disorder, Developmental0
1
2010201014.0low000100
Ache0
3
2002201713.0low200120
ACL Injuries0
1
202020204.0low000010
Acne0
1
202120213.0low000001
Acne Vulgaris0
1
202120213.0low000001
Acquired Metabolic Diseases, Brain0
1
2013201311.0low000010
Acquired-Immune Deficiency Syndrome Dementia Complex0
1
202020204.0low000010
Acrania0
1
2001200123.0low000100
Active Hyperemia0
1
2005200519.0low000100
Acute Bacterial Prostatitis0
1
1992199232.0low001000
Acute Confusional Senile Dementia0
25
1996202213.7low00211102
Acute Disease0
3
1997200820.7low001200
Acute Edematous Pancreatitis0
1
2007200717.0low000100
Acute Kidney Failure0
2
201920223.5low100011
Acute Kidney Injury0
2
201920223.5low100011
Acute Liver Injury, Drug-Induced0
2
2002201416.0low000110
Acute Lung Injury0
4
201320216.8low000031
Acute Myelogenous Leukemia0
1
2008200816.0low000100
Acute Onset Vascular Dementia0
2
201520168.5low000020
Acute Pain0
1
202220222.0low100001
Acute Relapsing Multiple Sclerosis0
1
202220222.0low100001
Adenocarcinoma0
36
1997202117.0low2052191
Adenocarcinoma Of Kidney0
1
1999199925.0low001000
Adenocarcinoma, Basal Cell0
36
1997202117.0low2052191
Adenocarcinoma, Clear Cell0
1
201620168.0low000010
Adenocarcinoma, Endometrioid0
2
2001200421.5low000200
Adenocarcinoma, Mucinous0
1
2014201410.0low000010
Adenoma0
5
2005201612.6low100230
Adenoma, Basal Cell0
5
2005201612.6low100230
Adenoma, Prostatic0
14
1988202117.4low012731
Adenomatous Polyposis Coli0
4
201320208.0low200040
Adenomatous Polyposis Coli, Familial0
4
201320208.0low200040
Adenomatous Polyps0
1
2007200717.0low000100
Adenosis of Breast0
1
2006200618.0low000100
Adjuvant Arthritis0
1
202220222.0low100001
Adolescent Gynecomastia0
3
200420219.0low000111
ADPKD0
1
1998199826.0low001000
Adrenal Cancer0
1
201720177.0low000010
Adrenal Cortex Cancer0
2
2010201014.0low000200
Adrenal Cortex Neoplasms0
2
2010201014.0low000200
Adrenocortical Carcinoma0
1
2010201014.0low000100
Adverse Drug Event0
1
2009200915.0low000100
Affective Disorders0
2
2003200619.5low000200
Age-Related Macular Degeneration0
1
202220222.0low100001
Age-Related Memory Disorders0
8
2006201313.9low000530
Age-Related Osteoporosis0
113
1995202315.0low00956444
Aggression0
5
2004202012.8low000230
Aging0
62
1996202315.2low10535193
Aging, Premature0
1
201920195.0low000010
AIDS Dementia Complex0
1
202020204.0low000010
AIRE Deficiency0
1
201620168.0low000010
Akinetic-Rigid Variant of Huntington Disease0
1
201620168.0low000010
Alcohol Abuse0
1
1991199133.0low001000
Alcohol Drinking0
16
1991201320.8low0041110
Alcoholism0
1
1991199133.0low001000
Allergic Contact Dermatitis0
1
201820186.0low000010
Allergic Reaction0
1
2006200618.0low000100
Allergic Rhinitis0
2
202220231.5low100002
Allergy, Milk0
2
2001200222.5low000200
Allodynia0
1
2008200816.0low000100
Alloxan Diabetes0
8
200820227.2low000152
Alopecia0
1
201920195.0low000010
Alopecia Areata0
1
2003200321.0low000100
Alopecia Cicatrisata0
1
201920195.0low000010
Alopecia Circumscripta0
1
2003200321.0low000100
ALS - Amyotrophic Lateral Sclerosis0
2
201920223.5low100011
Alveolitis, Fibrosing0
1
202120213.0low000001
Alzheimer Disease0
25
1996202213.7low00211102
Amenorrhea0
1
2004200420.0low100100
Amentia0
9
200120238.6low100252
Amyloid Deposits0
1
2013201311.0low000010
Amyotrophic Lateral Sclerosis0
2
201920223.5low100011
Anasarca0
2
201320169.5low000020
Androgen-Independent Prostatic Cancer0
1
2014201410.0low000010
Aneuploid0
2
2009201412.5low000110
Aneurysm, Anterior Cerebral Artery0
1
202120213.0low000001
Aneurysm, Arteriovenous0
1
2005200519.0low000100
Angina Pectoris0
1
2012201212.0low000010
Angiogenesis, Pathologic0
10
1996201219.3low104510
Angor Pectoris0
1
2012201212.0low000010
Animal Mammary Carcinoma0
6
2002201217.0low000510
Anovulation0
2
1993200525.0low001100
Anoxemia0
6
2001202112.7low000231
Anoxia-Ischemia, Brain0
1
201920195.0low000010
Anterior Choroidal Artery Infarction0
2
2006201115.5low000110
Anterior Circulation Transient Ischemic Attack0
1
2006200618.0low000100
Anxiety0
16
2001201913.4low500880
Anxiety Disorders0
2
201720196.0low000020
Anxiety Neuroses0
2
201720196.0low000020
Aortic Aneurysm, Abdominal0
1
2014201410.0low000010
Aortic Diseases0
2
2005201215.5low000110
Apnea, Obstructive Sleep0
4
201120209.5low000040
Apoplexy0
8
2000201714.9low001340
Arterial Diseases, Carotid0
1
2001200123.0low000100
Arteriosclerosis0
15
1998200821.7low0031200
Arteriosclerosis, Coronary0
11
1997202118.3low101811
Arthralgia0
1
2014201410.0low000010
Arthritis, Degenerative0
7
201020226.9low200151
Arthritis, Rheumatoid0
3
201620224.3low100012
Ascites0
1
2010201014.0low100100
Aseptic Necrosis of Bone0
2
2007201314.0low000110
Asthma0
4
200020237.2low201003
Asthma, Bronchial0
4
200020237.2low201003
Astrocytosis0
2
2007201214.5low000110
Atherogenesis0
13
2003201813.1low300760
Atheroma0
2
201420235.5low000011
Atherosclerosis0
13
2003201813.1low300760
Atherosclerotic Parkinsonism0
1
2009200915.0low000100
Atopic Hypersensitivity0
2
2008201015.0low000200
Atrophy0
13
2001202113.8low500661
Atrophy, Muscle0
3
2007201613.7low100210
Atypical Endometrial Hyperplasia0
10
2005202212.4low200541
Autism0
1
201620168.0low000010
Autistic Disorder0
1
201620168.0low000010
Autoimmune Diabetes0
5
200420199.4low000140
Autoimmune Disease0
2
201220236.5low000011
Autoimmune Diseases0
2
201220236.5low000011
Autoimmune Thyroiditis0
1
201620168.0low000010
Avitaminosis0
1
2001200123.0low000100
B16 Melanoma0
1
2004200420.0low000100
Back Ache0
1
2014201410.0low100010
Back Pain0
1
2014201410.0low100010
Bacterial Disease0
2
2005202210.5low100101
Bacterial Infections0
2
2005202210.5low100101
Bacterial Infections, Gram-Negative0
1
202220222.0low100001
Bacterial Infections, Gram-Positive0
1
202220222.0low100001
Behavior Disorders0
2
2002200421.0low100200
Benign Neoplasms0
93
1994202317.5low102734275
Benign Neoplasms, Brain0
2
2006202210.0low100101
Benign Paroxysmal Positional Vertigo0
1
201820186.0low000010
Berger Disease0
1
202220222.0low100001
Bertielliasis0
1
201720177.0low000010
Bilateral Headache0
2
2005200718.0low200200
Bile Duct Obstruction, Intrahepatic0
1
2012201212.0low000010
Biliary Calculi0
1
2009200915.0low000100
Birth Weight0
3
2008201810.3low000120
Bladder Cancer0
1
2006200618.0low000100
Bladder, Overactive0
1
2011201113.0low000010
Bleeding Between Periods0
2
2002200719.5low200200
Blood Clot0
4
2007201714.2low000310
Blood Poisoning0
1
201520159.0low000010
Blood Pressure, High0
20
2000202213.8low3011162
Body Weight0
114
1993202215.3low90860433
Body Weight, Fetal0
1
201820186.0low000010
Bone Cancer0
3
200720236.3low000102
Bone Diseases0
5
2001201317.2low000320
Bone Diseases, Metabolic0
14
2003201812.4low300590
Bone Fractures0
11
1998202314.1low001622
Bone Loss, Osteoclastic0
27
1998201714.2low30111150
Bone Loss, Perimenopausal0
118
1995202317.3low1102554372
Bone Neoplasms0
3
200720236.3low000102
Bone Spur0
1
2008200816.0low000100
Bovine Diseases0
2
1995201121.0low001010
Bowel Diseases, Inflammatory0
1
202220222.0low000001
Brain Inflammation0
2
2007202110.0low000101
Brain Ischemia0
11
200820228.8low200263
Brain Neoplasms0
2
2006202210.0low100101
Brain Vascular Disorders0
1
1982198242.0low010000
Branch Vein Occlusion0
1
2005200519.0low000100
Breast Cancer0
461
1984202316.5low1826625112319
Breast Cancer, Male0
3
2000201418.0low001110
Breast Carcinoma In Situ0
1
201720177.0low000010
Breast Diseases0
2
2005200618.5low100200
Breast Neoplasms0
461
1984202316.5low1826625112319
Breast Neoplasms, Male0
3
2000201418.0low001110
Breathlessness0
1
2014201410.0low100010
Bucket Handle Tears0
1
202220222.0low100001
Cancer of Cervix0
6
2004201414.5low000330
Cancer of Colon0
19
1998202015.1low102980
Cancer of Endometrium0
35
1993202216.5low10418121
Cancer of Esophagus0
2
201220227.0low100011
Cancer of Intestines0
1
2005200519.0low000100
Cancer of Kidney0
1
1999199925.0low001000
Cancer of Liver0
14
1998202016.2low003560
Cancer of Lung0
13
2001202212.4low000742
Cancer of Mouth0
1
2008200816.0low000100
Cancer of Ovary0
23
1993202213.0low2017123
Cancer of Pancreas0
4
1999200523.5low003100
Cancer of Pelvis0
1
2011201113.0low000010
Cancer of Pituitary0
5
1998200918.8low001400
Cancer of Prostate0
141
1993202316.9low1002181309
Cancer of Rectum0
1
2010201014.0low000100
Cancer of Skin0
1
2004200420.0low000100
Cancer of Stomach0
10
2001202210.5low200262
Cancer of Testis0
2
2002201316.5low000110
Cancer of the Thyroid0
4
200220228.2low100121
Cancer of the Uterus0
13
2001202315.8low000841
Cancer of the Vulva0
1
2001200123.0low000100
Cancer, Embryonal0
1
2013201311.0low000010
Cancer, Radiation-Induced0
1
2000200024.0low001000
Cancer, Second Primary0
1
2000200024.0low001000
Carcinogenesis0
2
201620206.0low000020
Carcinoma0
12
2000201217.6low003720
Carcinoma, Anaplastic0
12
2000201217.6low003720
Carcinoma, Colloid0
1
2014201410.0low000010
Carcinoma, Ductal, Breast0
1
2014201410.0low000010
Carcinoma, Endometrioid0
2
2001200421.5low000200
Carcinoma, Epidermoid0
2
2001201217.5low000110
Carcinoma, Hepatocellular0
12
1998202015.2low001560
Carcinoma, Non-Small Cell Lung0
2
2008202010.0low000110
Carcinoma, Non-Small-Cell Lung0
2
2008202010.0low000110
Carcinoma, Ovarian Epithelial0
2
201120227.5low100011
Carcinoma, Papillary0
1
2014201410.0low000010
Carcinoma, Renal Cell0
1
1999199925.0low001000
Carcinoma, Squamous Cell0
2
2001201217.5low000110
Carcinoma, Transitional Cell0
1
2006200618.0low000100
Cardiac Death0
1
202220222.0low100001
Cardiac Diseases0
10
1994201718.9low002620
Cardiac Failure0
2
2008201214.0low000110
Cardiac Hypertrophy0
2
2008200915.5low000200
Cardiac Output, Low0
1
2005200519.0low000100
Cardiac Remodeling, Ventricular0
4
2005202213.5low100301
Cardiac Toxicity0
1
202020204.0low000010
Cardiomegaly0
2
2008200915.5low000200
Cardiometabolic Syndrome0
14
200820228.9low3001121
Cardiomyopathies0
1
201820186.0low000010
Cardiomyopathies, Primary0
1
201820186.0low000010
Cardiomyopathy, Hypertrophic0
1
202220222.0low100001
Cardiomyopathy, Hypertrophic Obstructive0
1
202220222.0low100001
Cardiotoxicity0
1
202020204.0low000010
Cardiovascular Diseases0
139
1996202317.3low2103066385
Cardiovascular Stroke0
9
2004201615.4low000720
Carotid Artery Diseases0
1
2001200123.0low000100
Cat Diseases0
1
1987198737.0low010000
Catarrh0
1
202220222.0low100001
Cell Transformation, Neoplastic0
9
2000201817.2low002430
Central Hypothyroidism0
3
201120226.3low200021
Central Nervous System Origin Vertigo0
1
201720177.0low100010
Cerebral Infarction0
2
2006201115.5low000110
Cerebral Infarction, Middle Cerebral Artery0
3
200720229.7low100111
Cerebral Ischemia0
11
200820228.8low200263
Cerebrovascular Disorders0
1
1982198242.0low010000
Cervix Diseases0
1
2010201014.0low000100
Cervix Dysplasia0
1
2004200420.0low000100
Chemical and Drug Induced Liver Injury0
2
2002201416.0low000110
Chemical Dependence0
1
1991199133.0low001000
Cholera Infantum0
1
2009200915.0low000100
Cholestasis, Intrahepatic0
1
2012201212.0low000010
Choriocarcinoma0
1
2012201212.0low000010
Chromosome-Defective Micronuclei0
2
2005201315.0low000110
Chronic Disease0
14
1999202213.9low101652
Chronic Hepatitis C0
2
202220222.0low200002
Chronic Illness0
14
1999202213.9low101652
Chronic Insomnia0
3
2007201711.0low300120
Chronic Kidney Disease-Mineral and Bone Disorder0
1
2002200222.0low000100
Chronic Kidney Failure0
6
1998202219.8low102301
Chronic Lung Injury0
1
202120213.0low000001
Chylopericardium0
2
2010201611.0low100110
Cirrhosis0
4
200720236.5low000112
Cirrhosis, Liver0
5
200220229.0low100203
CKD-MBD0
1
2002200222.0low000100
Classic Galactosemia0
1
2011201113.0low000010
Co-infection0
1
202220222.0low100001
Cocaine Abuse0
1
202120213.0low000001
Cocaine-Related Disorders0
1
202120213.0low000001
Cocarcinogenesis0
2
2003201216.5low000110
Cognition Disorders0
6
2001201614.0low200330
Cognitive Decline0
11
201620224.5low100074
Cognitive Dysfunction0
11
201620224.5low100074
Colitis0
2
200820229.0low000101
Colitis Gravis0
2
201420207.0low100020
Colitis, Mucous0
1
2013201311.0low000010
Colitis, Ulcerative0
2
201420207.0low100020
Colon Cancer, Familial Nonpolyposis0
1
201520159.0low000010
Colonic Neoplasms0
19
1998202015.1low102980
Colonic Polyps0
1
2013201311.0low100010
Colorectal Cancer0
26
1995202211.8low10111104
Colorectal Neoplasms0
26
1995202211.8low10111104
Colorectal Neoplasms, Hereditary Nonpolyposis0
1
201520159.0low000010
Common Cold0
1
202220222.0low100001
Compensatory Hyperinsulinemia0
1
2008200816.0low100100
Complication, Postoperative0
3
200620227.3low200102
Condition, Preneoplastic0
1
201520159.0low000010
Congenital Fissure of the Abdominal Cavity0
1
201620168.0low000010
Congenital Hypothyroidism0
2
2006200618.0low000200
Contact Dermatitis0
1
2012201212.0low000010
Coronary Artery Disease0
11
1997202118.3low101811
Coronary Disease0
27
1982201822.8low11121310
Coronary Heart Disease0
27
1982201822.8low11121310
Coronary Restenosis0
1
2006200618.0low000100
Coronavirus Infections0
3
202020222.7low200012
Cough0
1
2014201410.0low100010
Cranial Sinus Thrombosis0
1
2005200519.0low000100
Cretinism0
2
2006200618.0low000200
Cystadenocarcinoma, Serous0
1
201620168.0low000010
Cystic Fibrosis0
1
2011201113.0low000010
Cystic Fibrosis of Pancreas0
1
2011201113.0low000010
Cytokine Release Syndrome0
1
202020204.0low000010
Day Blindness0
1
2011201113.0low000010
Deep Vein Thrombosis0
1
2008200816.0low000100
Deficiency Diseases0
1
2006200618.0low000100
Deficiency, Folic Acid0
1
201720177.0low000010
Deficiency, Protein S0
1
2005200519.0low000100
Deficiency, Vitamin A0
1
2003200321.0low000100
Deficiency, Vitamin B 120
1
201920195.0low000010
Deficiency, Vitamin D0
2
2003200918.0low000200
Deficiency, Vitamin K0
1
2003200321.0low000100
Degenerative Diseases, Central Nervous System0
9
2005202012.8low000540
Dehydration0
1
2005200519.0low000100
Delayed Effects, Prenatal Exposure0
42
1993202314.5low00317211
Delayed Hypersensitivity0
1
2007200717.0low000100
Delayed Puberty0
1
2002200222.0low000100
Dementia0
9
200120238.6low100252
Dementia Praecox0
1
201820186.0low000010
Dementia, Vascular0
2
201520168.5low000020
Depression0
19
200220229.8low6004123
Depression, Endogenous0
4
2003201910.8low100130
Depressive Disorder0
4
2003201910.8low100130
Dermatitis, Allergic Contact0
1
201820186.0low000010
Dermatitis, Atopic0
1
202120213.0low000001
Dermatitis, Contact0
1
2012201212.0low000010
Dermatoses0
2
2000201417.0low101010
Diabetes Mellitus0
4
2002201713.2low000220
Diabetes Mellitus, Adult-Onset0
19
200220239.6low4005104
Diabetes Mellitus, Type 10
5
200420199.4low000140
Diabetes Mellitus, Type 20
19
200220239.6low4005104
Diabetic Angiopathies0
1
2002200222.0low100100
Diabetic Glomerulosclerosis0
1
2004200420.0low000100
Diabetic Nephropathies0
1
2004200420.0low000100
Diabetic Retinopathy0
2
2005202111.0low000101
Diathesis0
7
1999202216.6low101411
Digestive System Diseases0
1
2012201212.0low000010
Digestive System Disorders0
1
2012201212.0low000010
Disbacteriosis0
2
201820233.5low000011
Disease0
1
2008200816.0low000100
Disease Exacerbation0
13
1998201516.8low101660
Disease Models, Animal0
145
1996202213.2low00564706
Diseases of Endocrine System0
3
2007201215.0low000210
Diseases, Metabolic0
2
201820195.5low000020
Dizziness0
1
2007200717.0low100100
Dizzyness0
1
2007200717.0low100100
Drug-Related Side Effects and Adverse Reactions0
1
2009200915.0low000100
Dry Eye0
1
2012201212.0low100010
Dry Eye Syndromes0
1
2012201212.0low100010
Duodenal Diseases0
1
2013201311.0low100010
Dyskinesia Syndromes0
1
2008200816.0low000100
Dyslipidemia0
8
200820239.4low200251
Dyslipidemias0
8
200820239.4low200251
Dysmenorrhea0
2
2008201015.0low000200
Dyspareunia0
6
201020198.5low300150
Dyspnea0
1
2014201410.0low100010
E coli Infections0
1
202220222.0low100001
Eczema, Atopic0
1
202120213.0low000001
Edema0
2
201320169.5low000020
Edema, Pulmonary0
1
2013201311.0low000010
Electrocardiogram QT Prolonged0
1
2001200123.0low000100
Electrolytes0
1
202220222.0low100001
Elevated Cholesterol0
11
2002201417.9low4001010
Encephalitis0
2
2007202110.0low000101
Endemic Goiter0
1
2000200024.0low001000
Endocrine System Diseases0
3
2007201215.0low000210
Endometrial Diseases0
1
2011201113.0low000010
Endometrial Hyperplasia0
10
2005202212.4low200541
Endometrial Neoplasms0
35
1993202216.5low10418121
Endometrioma0
10
200820237.8low100253
Endometriosis0
10
200820237.8low100253
Epithelial Neoplasms0
1
2011201113.0low000010
Epithelial Ovarian Cancer0
2
201120227.5low100011
ER-Negative PR-Negative HER2-Negative Breast Cancer0
1
201820186.0low000010
Erectile Dysfunction0
5
2003201413.0low000140
Escherichia coli Infections0
1
202220222.0low100001
Esophageal Neoplasms0
2
201220227.0low100011
Experimental Mammary Neoplasms0
28
1996201717.4low0032050
Experimental Neoplasms0
10
1994202218.2low103421
Extravascular Hemolysis0
1
2011201113.0low000010
Familial Nonmedullary Thyroid Cancer0
1
201920195.0low000010
Familial Precocious Puberty0
6
2002201316.7low000510
Fatigue0
1
2011201113.0low000010
Fatty Liver0
7
2009202010.3low100250
Fatty Liver, Nonalcoholic0
13
200920236.0low000193
Female Genital Diseases0
3
1999200423.0low002100
Female Genital Neoplasms0
1
2010201014.0low000100
Female Genitourinary Diseases0
4
2004202110.8low200202
Feminization0
4
1995202211.0low001012
Femoral Fractures0
1
2013201311.0low000010
Fetal Death0
2
2001200521.0low000200
Fibroadenoma0
1
2003200321.0low100100
Fibrocystic Breast Disease0
1
2006200618.0low000100
Fibroid0
6
200620238.8low000222
Fibroma0
1
2011201113.0low000010
Fibromatosis0
1
2011201113.0low000010
Fibrosis0
4
200720236.5low000112
Fish Diseases0
1
202220222.0low100001
Flatulence0
1
2008200816.0low000100
Flatus0
1
2008200816.0low000100
Flushing0
1
1995199529.0low101000
Folic Acid Deficiency0
1
201720177.0low000010
Food Poisoning0
1
2012201212.0low000010
Fracture, Pathologic0
1
201520159.0low000010
Fractures, Bone0
11
1998202314.1low001622
Frigidity0
1
2013201311.0low000010
Galactosemias0
1
2011201113.0low000010
Gallstones0
1
2009200915.0low000100
Gargoylism, Hunter Syndrome0
1
2010201014.0low000100
Gastroschisis0
1
201620168.0low000010
Genetic Predisposition0
11
2000202215.5low101631
Genital Diseases, Female0
3
1999200423.0low002100
Genital Diseases, Male0
3
1993201320.3low001110
Genital Neoplasms, Female0
1
2010201014.0low000100
Genome Instability0
1
2005200519.0low000100
Germinoblastoma0
1
2006200618.0low000100
Germinoma0
1
2002200222.0low000100
Giant Osteoid Osteoma0
1
2003200321.0low000100
Gingivitis0
1
2009200915.0low000100
Glaucoma, Suspect0
1
2011201113.0low000010
Glial Cell Tumors0
1
2006200618.0low000100
Glioma0
1
2006200618.0low000100
Glomerulonephritis, IGA0
1
202220222.0low100001
Glucose Intolerance0
4
201220179.2low000040
Glucose Metabolic Disorder0
1
2006200618.0low000100
Goiter0
1
2006200618.0low000100
Gonadal Agenesis0
1
2007200717.0low000100
Gram-Negative Bacterial Infections0
1
202220222.0low100001
Gram-Positive Bacterial Infections0
1
202220222.0low100001
Growth Disorders0
1
2014201410.0low000010
Gynecomastia0
3
200420219.0low000111
Hay Fever0
1
2008200816.0low000100
Headache0
2
2005200718.0low200200
Heart Disease, Ischemic0
8
2000202215.0low101412
Heart Diseases0
10
1994201718.9low002620
Heart Failure0
2
2008201214.0low000110
Heavy Metal Poisoning0
1
2005200519.0low000100
Hemolysis0
1
2011201113.0low000010
Hemorrhage, Uterine0
5
2008201613.0low100320
Hepatic Veno Occlusive Disease0
2
1987198737.0low020000
Hepatic Veno-Occlusive Disease0
2
1987198737.0low020000
Hepatitis C0
1
202220222.0low100001
Hepatitis C, Chronic0
2
202220222.0low200002
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0
1
202220222.0low100001
Hepatocellular Carcinoma0
12
1998202015.2low001560
Hereditary Optic Neuroretinopathy0
1
201520159.0low000010
Hibernation, Myocardial0
1
202020204.0low000010
Hip Fractures0
1
2012201212.0low000010
Hirsutism0
1
2000200024.0low101000
HIV Coinfection0
4
202020222.5low300013
HIV Infections0
4
202020222.5low300013
Hormone-Dependent Neoplasms0
30
1984201720.2low0171840
Hot Flashes0
156
1998202314.9low3701173702
HPV Infection0
2
2004200420.0low000200
Huntington Disease0
1
201620168.0low000010
Hypercholesterolemia0
11
2002201417.9low4001010
Hypercoagulability0
1
202020204.0low000010
Hyperemia0
1
2005200519.0low000100
Hyperglycemia0
3
201220178.7low100030
Hyperglycemia, Postprandial0
3
201220178.7low100030
Hypergonadotropic Hypogonadism0
5
2003202211.6low200221
Hyperhomocysteinemia0
2
2011201411.5low000020
Hyperinsulinism0
1
2008200816.0low100100
Hyperlipemia0
8
2002202013.5low000440
Hyperlipidemias0
8
2002202013.5low000440
Hyperlipoproteinemia0
1
202320231.0low000001
Hyperlipoproteinemias0
1
202320231.0low000001
Hyperoxia0
1
202120213.0low000001
Hyperplasia0
8
2004201912.8low200350
Hyperplasia, Reactive Lymphoid0
1
2008200816.0low000100
Hypersensitivity0
1
2006200618.0low000100
Hypertension0
20
2000202213.8low3011162
Hypertension, Pulmonary0
4
2001201714.0low100220
Hypertriglyceridemia0
1
201620168.0low000010
Hypertrophy0
4
1995202214.2low101111
Hypertrophy, Left Ventricular0
2
2005200718.0low000200
Hypocalcemia0
1
2013201311.0low000010
Hypogonadism0
5
2003202211.6low200221
Hypomenorrhea0
1
2002200222.0low000100
Hypophosphatemia0
1
2013201311.0low000010
Hypospadias0
6
2000201315.0low001140
Hypospermatogenesis0
2
2006201314.5low000110
Hypothyroidism0
3
201120226.3low200021
Hypoxia0
6
2001202112.7low000231
Hypoxia-Ischemia, Brain0
1
201920195.0low000010
Idiopathic Parkinson Disease0
4
2003202115.5low000301
Impaired Glucose Tolerance0
4
201220179.2low000040
Impotence0
5
2003201413.0low000140
Infant Malnutrition0
1
2001200123.0low000100
Infant, Newborn, Diseases0
1
2008200816.0low000100
Infarction, Middle Cerebral Artery0
3
200720229.7low100111
Infections, Coronavirus0
3
202020222.7low200012
Infections, Plasmodium0
1
2007200717.0low000100
Infections, Staphylococcal0
1
202220222.0low100001
Infections, Staphylococcal Skin0
1
201720177.0low000010
Infertility0
7
1995201915.4low201240
Infertility, Female0
15
1981201225.1low343620
Infertility, Male0
14
2002202014.1low000770
Inflammation0
43
200120227.9low70092410
Inflammatory Bowel Diseases0
1
202220222.0low000001
Injuries, Tendon0
1
201720177.0low000010
Injury, Ischemia-Reperfusion0
10
2001202211.6low200352
Injury, Myocardial Reperfusion0
4
2004202012.5low000220
Innate Inflammatory Response0
43
200120227.9low70092410
Insulin Resistance0
24
2002202210.5low3006153
Insulin Sensitivity0
24
2002202210.5low3006153
Intermittent Claudication0
1
202220222.0low100001
Intertrochanteric Fractures0
1
2012201212.0low000010
Intestinal Neoplasms0
1
2005200519.0low000100
Intestinal Polyps0
2
201320169.5low200020
Intracranial Aneurysm0
1
202120213.0low000001
Intraepithelial Prostatic Neoplasia0
1
1996199628.0low001000
Intraocular Pressure0
1
2011201113.0low000010
Invasiveness, Neoplasm0
7
2002202210.1low200151
Irritable Bowel Syndrome0
1
2013201311.0low000010
Ischemia0
3
200920218.3low000111
Ischemic Attack, Transient0
1
2006200618.0low000100
Jactatio Capitis Nocturna0
1
201620168.0low000010
Joint Pain0
1
2014201410.0low000010
Kidney Diseases0
2
201320226.5low000011
Kidney Failure, Chronic0
6
1998202219.8low102301
Kidney Neoplasms0
1
1999199925.0low001000
Koch's Disease0
1
2004200420.0low000100
Lassitude0
1
2011201113.0low000010
LCIS, Lobular Carcinoma In Situ0
1
201720177.0low000010
Learning Disabilities0
1
2010201014.0low000100
Left Ventricular Hypertrophy0
2
2005200718.0low000200
Leiomyoma0
6
200620238.8low000222
Lesion of Sciatic Nerve0
1
2008200816.0low000100
Leucocythaemia0
2
201520206.5low000020
Leukemia0
2
201520206.5low000020
Leukemia, Acute Monocytic0
1
2008200816.0low000100
Leukemia, Monocytic, Acute0
1
2008200816.0low000100
Leukemia, Myeloid, Acute0
1
2008200816.0low000100
Libman-Sacks Disease0
4
2004202214.0low100301
Liver Cirrhosis0
5
200220229.0low100203
Liver Diseases0
4
1987201419.8low010120
Liver Dysfunction0
4
1987201419.8low010120
Liver Neoplasms0
14
1998202016.2low003560
Liver Steatosis0
7
2009202010.3low100250
Local Neoplasm Recurrence0
7
2000202214.0low201312
Long QT Syndrome0
1
2001200123.0low000100
Long Sleeper Syndrome0
7
2002202010.0low200160
Low Back Ache0
1
202220222.0low100001
Low Back Pain0
1
202220222.0low100001
Low Bone Density0
14
2003201812.4low300590
Lung Injury, Acute0
4
201320216.8low000031
Lung Neoplasms0
13
2001202212.4low000742
Lupus Erythematosus, Systemic0
4
2004202214.0low100301
Lymph Node Metastasis0
3
2002201416.7low000210
Lymphoma0
1
2006200618.0low000100
Lymphoma, T-Cell0
1
2005200519.0low000100
Lysosomal Enzyme Disorders0
1
201520159.0low000010
Macular Degeneration0
1
202220222.0low100001
Malaria0
1
2007200717.0low000100
Malaria, Falciparum0
1
202220222.0low100001
Malnourishment0
1
202020204.0low000010
Malnutrition0
1
202020204.0low000010
Mastitis, Bovine0
2
2003201117.0low000110
Memory Disorders0
8
2006201313.9low000530
Meniscitis0
1
201620168.0low000010
Menopause0
268
1991202316.2low29039132898
Menopause, Premature0
3
2000201118.3low001110
Menstruation, Painful0
2
2008201015.0low000200
Mental Disorders0
2
2002200421.0low100200
Metabolic Diseases0
2
201820195.5low000020
Metabolic Syndrome0
14
200820228.9low3001121
Metastase0
4
201020208.2low000130
Metrorrhagia0
2
2002200719.5low200200
Migraine Disorders0
2
2002200719.5low100200
Milk Hypersensitivity0
2
2001200222.5low000200
Monkey Diseases0
1
2014201410.0low100010
Mood Disorders0
2
2003200619.5low000200
Mouth Diseases0
1
2009200915.0low000100
Mouth Neoplasms0
1
2008200816.0low000100
Movement Disorders0
1
2008200816.0low000100
MPTP Neurotoxicity Syndrome0
1
201520159.0low000010
MS (Multiple Sclerosis)0
4
201820233.5low100022
Mucopolysaccharidoses0
1
201520159.0low000010
Mucopolysaccharidosis0
1
201520159.0low000010
Mucopolysaccharidosis II0
1
2010201014.0low000100
Mucositis0
1
202020204.0low000010
Mucositis, Oral0
1
202020204.0low000010
Multiple Primary Neoplasms0
1
2005200519.0low000100
Multiple Sclerosis0
4
201820233.5low100022
Multiple Sclerosis, Relapsing-Remitting0
1
202220222.0low100001
Muscle Contraction0
16
1998201416.1low002860
Muscle Pain0
1
2014201410.0low000010
Muscle Relaxation0
3
2009201312.7low000120
Muscular Atrophy0
3
2007201613.7low100210
Myalgia0
1
2014201410.0low000010
Myocardial Infarction0
9
2004201615.4low000720
Myocardial Ischemia0
8
2000202215.0low101412
Necrosis0
2
2000200820.0low001100
Neoplasm Metastasis0
4
201020208.2low000130
Neoplasms0
93
1994202317.5low102734275
Neoplasms, Germ Cell and Embryonal0
1
2013201311.0low000010
Neoplasms, Trophoblastic0
2
201320169.5low000020
Nerve Degeneration0
1
2007200717.0low000100
Nerve Pain0
1
2002200222.0low000100
Nervous System Diseases0
2
201620234.5low000011
Nervous System Disorders0
2
201620234.5low000011
Neural Tube Defects0
1
2001200123.0low000100
Neuralgia0
1
2002200222.0low000100
Neuroblastoma0
5
2009202210.2low100311
Neurodegenerative Diseases0
9
2005202012.8low000540
Non-alcoholic Fatty Liver Disease0
13
200920236.0low000193
Obesity0
51
1995202211.8low70314304
Ocular Hypertension0
1
2011201113.0low000010
Oligomenorrhea0
1
201620168.0low000010
Oophoritis0
1
201620168.0low000010
Optic Atrophy, Hereditary, Leber0
1
201520159.0low000010
Osteoarthritis0
7
201020226.9low200151
Osteoarthritis of Knee0
3
2002200819.3low000300
Osteoarthritis, Knee0
3
2002200819.3low000300
Osteogenic Sarcoma0
8
2000202314.5low001511
Osteolysis0
2
201020237.5low000101
Osteonecrosis0
2
2007201314.0low000110
Osteoporosis0
113
1995202315.0low00956444
Osteoporosis, Postmenopausal0
118
1995202317.3low1102554372
Osteoporotic Fractures0
3
201220208.7low000030
Osteosarcoma0
8
2000202314.5low001511
Ovarian Neoplasms0
23
1993202213.0low2017123
Overweight0
6
2011201710.3low400060
Ovine Diseases0
5
1981199636.8low032000
Pain0
3
2002201713.0low200120
Pancreatic Neoplasms0
4
1999200523.5low003100
Pancreatitis0
1
2007200717.0low000100
Papillomavirus Infections0
2
2004200420.0low000200
Parkinson Disease0
4
2003202115.5low000301
Parkinson Disease, Secondary0
1
2009200915.0low000100
Pericardial Effusion0
2
2010201611.0low100110
Peripheral Arterial Disease0
1
202220222.0low100001
Peripheral Arterial Diseases0
1
202220222.0low100001
Peripheral Nerve Diseases0
1
2008200816.0low000100
Peripheral Nervous System Diseases0
1
2008200816.0low000100
Pheochromocytoma0
1
201720177.0low000010
Pheochromocytoma, Extra-Adrenal0
1
201720177.0low000010
Pituitary Neoplasms0
5
1998200918.8low001400
Plant Poisoning0
2
1983199634.5low011000
Plasmodium falciparum Malaria0
1
202220222.0low100001
Plica Syndrome0
1
201620168.0low000010
Pneumonia, Viral0
3
202020222.7low200012
Polycystic Kidney, Autosomal Dominant0
1
1998199826.0low001000
Polycystic Ovarian Syndrome0
10
200820227.3low200172
Polycystic Ovary Syndrome0
10
200820227.3low200172
Postoperative Complications0
3
200620227.3low200102
Postpartum Amenorrhea0
1
2004200420.0low100100
Poultry Diseases0
2
2010201710.5low100110
Pre-Hypertension0
3
201320169.3low300030
Precancerous Conditions0
1
201520159.0low000010
Pregnancy0
169
1981202314.3low7210777010
Premature Birth0
1
2011201113.0low000010
Premenstrual Syndrome0
3
2005201813.0low200210
Premenstrual Tension0
3
2005201813.0low200210
Preterm Birth0
1
2011201113.0low000010
Prostatic Diseases0
2
1998201219.0low001010
Prostatic Hyperplasia0
14
1988202117.4low012731
Prostatic Intraepithelial Neoplasia0
1
1996199628.0low001000
Prostatic Neoplasms0
141
1993202316.9low1002181309
Prostatic Neoplasms, Castration-Resistant0
1
2014201410.0low000010
Prostatitis0
1
1992199232.0low001000
Puberty, Precocious0
6
2002201316.7low000510
Pulmonary Arterial Remodeling0
1
202120213.0low000001
Pulmonary Edema0
1
2013201311.0low000010
Pulmonary Fibrosis0
1
202120213.0low000001
Pulmonary Hypertension0
4
2001201714.0low100220
Recrudescence0
4
201020209.0low000130
Rectal Neoplasms0
1
2010201014.0low000100
Reperfusion Injury0
10
2001202211.6low200352
Reproductive Sterility0
7
1995201915.4low201240
Respiratory Tract Diseases0
1
202220222.0low100001
Retinal Diseases0
1
2011201113.0low000010
Retinal Vein Occlusion0
1
2005200519.0low000100
Rheumatoid Arthritis0
3
201620224.3low100012
Rhinitis, Allergic0
2
202220231.5low100002
Rhinitis, Allergic, Seasonal0
1
2008200816.0low000100
Sarcoma0
1
202220222.0low100001
Sarcoma, Epithelioid0
1
202220222.0low100001
Sarcopenia0
2
201720224.5low100011
Schizophrenia0
1
201820186.0low000010
Segond Fracture0
1
2008200816.0low000100
Seizures0
5
201220187.8low000050
Seminoma0
1
2002200222.0low000100
Sensitivity and Specificity0
34
1998202119.9low0092221
Sepsis0
1
201520159.0low000010
Sex Disorders0
5
2009201810.2low300230
Sexual Dysfunction, Physiological0
5
2009201810.2low300230
Sexual Dysfunctions, Psychological0
1
2013201311.0low000010
Shock, Cardiogenic0
1
202220222.0low100001
Sinus Infections0
1
202220222.0low100001
Sinusitis0
1
202220222.0low100001
Skin Aging0
6
201120209.2low100060
Skin Diseases0
2
2000201417.0low101010
Skin Neoplasms0
1
2004200420.0low000100
Sleep Apnea, Obstructive0
4
201120209.5low000040
Sleep Initiation and Maintenance Disorders0
3
2007201711.0low300120
Sleep Wake Disorders0
7
2002202010.0low200160
Smoking Cessation0
1
2012201212.0low000010
Staphylococcal Infections0
1
202220222.0low100001
Staphylococcal Skin Infections0
1
201720177.0low000010
Sterility, Female0
15
1981201225.1low343620
Sterility, Male0
14
2002202014.1low000770
Stomach Neoplasms0
10
2001202210.5low200262
Stomatitis0
1
202020204.0low000010
Stroke0
8
2000201714.9low001340
Stunted Growth0
1
2014201410.0low000010
Substance-Related Disorders0
1
1991199133.0low001000
Symptom Cluster0
4
1993202114.2low101111
Syndrome0
4
1993202114.2low101111
Synovitis0
1
201620168.0low000010
T-Cell Lymphoma0
1
2005200519.0low000100
Taste Disorder, Anterior Tongue0
1
2009200915.0low000100
Testicular Diseases0
1
2005200519.0low000100
Testicular Neoplasms0
2
2002201316.5low000110
Thromboembolism0
2
2004200420.0low000200
Thromboembolism, Venous0
2
2008201811.0low000110
Thrombophilia0
1
202020204.0low000010
Thrombosis0
4
2007201714.2low000310
Thyroid Diseases0
1
2004200420.0low000100
Thyroid Neoplasms0
4
200220228.2low100121
Tibial Fractures0
1
2008200816.0low000100
Triple Negative Breast Neoplasms0
1
201820186.0low000010
Tuberculosis0
1
2004200420.0low000100
Urinary Bladder Neoplasms0
1
2006200618.0low000100
Urinary Bladder, Overactive0
1
2011201113.0low000010
Urinary Incontinence0
2
2010201312.5low000110
Urinary Tract Diseases0
1
202120213.0low000001
Urination Disorders0
1
2005200519.0low000100
Uterine Cervical Dysplasia0
1
2004200420.0low000100
Uterine Cervical Neoplasms0
6
2004201414.5low000330
Uterine Diseases0
1
2011201113.0low000010
Uterine Hemorrhage0
5
2008201613.0low100320
Uterine Neoplasms0
13
2001202315.8low000841
Vaginal Diseases0
9
2000201813.7low701350
Vaginitis0
1
2011201113.0low100010
Vascular Calcification0
3
201420216.7low000021
Vascular Diseases0
1
2010201014.0low000100
Venous Thromboembolism0
2
2008201811.0low000110
Venous Thrombosis0
1
2008200816.0low000100
Ventricular Fibrillation0
1
2001200123.0low000100
Vertigo0
1
201720177.0low100010
Viral Diseases0
1
2009200915.0low000100
Virus Diseases0
1
2009200915.0low000100
Vitamin A Deficiency0
1
2003200321.0low000100
Vitamin B 12 Deficiency0
1
201920195.0low000010
Vitamin D Deficiency0
2
2003200918.0low000200
Vitamin K Deficiency0
1
2003200321.0low000100
Vulvar Diseases0
1
201820186.0low100010
Vulvar Neoplasms0
1
2001200123.0low000100
Water-Electrolyte Imbalance0
1
2013201311.0low000010
Weight Gain0
22
2000202213.0low1011182
Weight Loss0
1
2012201212.0low100010
Weight Reduction0
1
2012201212.0low100010

Safety/Toxicity (68)

ArticleYear
Hepatotoxic effect of dietary phytoestrogens on juvenile cultured Russian sturgeon (Acipenser gueldenstaedtii).
Aquatic toxicology (Amsterdam, Netherlands), , Volume: 261		2023
The potential of pumpkin seed oil as a functional food-A comprehensive review of chemical composition, health benefits, and safety.
Comprehensive reviews in food science and food safety, , Volume: 21, Issue:5		2022
Ferutinin: A phytoestrogen from ferula and its anticancer, antioxidant, and toxicity properties.
Journal of biochemical and molecular toxicology, , Volume: 35, Issue:4		2021
Equol Pretreatment Protection of SH-SY5Y Cells against Aβ (25-35)-Induced Cytotoxicity and Cell-Cycle Reentry via Sustaining Estrogen Receptor Alpha Expression.
Nutrients, , Oct-03, Volume: 11, Issue:10		2019
Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy.
Nutrition and cancer, , Volume: 71, Issue:8		2019
Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Mar-15, Volume: 56		2019
Toxicity and non-harmful effects of the soya isoflavones, genistein and daidzein, in embryos of the zebrafish, Danio rerio.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, , Volume: 211		2018
EB 2017 Article: Soy protein isolate feeding does not result in reproductive toxicity in the pre-pubertal rat testis.
Experimental biology and medicine (Maywood, N.J.), , Volume: 243, Issue:8		2018
Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women.
Menopause (New York, N.Y.), , Volume: 25, Issue:2		2018
Safety evaluation of daidzein in laying hens: Effects on laying performance, hatchability, egg quality, clinical blood parameters, and organ development.
Poultry science, , Jul-01, Volume: 96, Issue:7		2017
European medicinal and edible plants associated with subacute and chronic toxicity part I: Plants with carcinogenic, teratogenic and endocrine-disrupting effects.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 92		2016
Effects of daidzein in regards to cytotoxicity in vitro, apoptosis, reactive oxygen species level, cell cycle arrest and the expression of caspase and Bcl-2 family proteins.
Oncology reports, , Volume: 34, Issue:3		2015
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
PloS one, , Volume: 10, Issue:3		2015
Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor.
Molecular and cellular endocrinology, , Jan-05, Volume: 399		2015
The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.
Nutrients, , Oct-21, Volume: 6, Issue:10		2014
Efficacy and safety of a phyto-SERM as an alternative to hormone therapy.
Climacteric : the journal of the International Menopause Society, , Volume: 18, Issue:3		2015
Improvements of vaginal atrophy without systemic side effects after topical application of Pueraria mirifica, a phytoestrogen-rich herb, in postmenopausal cynomolgus macaques.
The Journal of reproduction and development, , Volume: 60, Issue:3		2014
Healthy and adverse effects of plant-derived functional metabolites: the need of revealing their content and bioactivity in a complex food matrix.
Critical reviews in food science and nutrition, , Volume: 53, Issue:2		2013
Testing of the estrogenic activity and toxicity of Stephania venosa herb in ovariectomized rats.
Toxicology mechanisms and methods, , Volume: 22, Issue:6		2012
NTP-CERHR expert panel report on the developmental toxicity of soy infant formula.
Birth defects research. Part B, Developmental and reproductive toxicology, , Volume: 92, Issue:5		2011
The neuroprotective effects of phytoestrogen α-zearalanol on β-amyloid-induced toxicity in differentiated PC-12 cells.
European journal of pharmacology, , Nov-30, Volume: 670, Issue:2-3		2011
Nutraceutical value and safety of tomato fruits produced by mycorrhizal plants.
The British journal of nutrition, , Volume: 107, Issue:2		2012
Combined developmental toxicity of bisphenol A and genistein in micromass cultures of rat embryonic limb bud and midbrain cells.
Toxicology in vitro : an international journal published in association with BIBRA, , Volume: 25, Issue:1		2011
Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 48, Issue:12		2010
Retinal toxicity of intravitreal genistein in a rabbit model.
Retina (Philadelphia, Pa.), , Volume: 30, Issue:9		2010
Comparable attenuation of Abeta(25-35)-induced neurotoxicity by quercitrin and 17beta-estradiol in cultured rat hippocampal neurons.
Neurochemical research, , Volume: 35, Issue:8		2010
Safety of herbal medicinal products in women with breast cancer.
Maturitas, , Volume: 66, Issue:4		2010
Inhibitory effect of estrogens, phytoestrogens, and caloric restriction on oxidative stress and hepato-toxicity in aged rats.
Biomedical and environmental sciences : BES, , Volume: 22, Issue:5		2009
Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways.
Journal of ethnopharmacology, , Jan-08, Volume: 127, Issue:1		2010
The adverse effect of phytoestrogens on the synthesis and secretion of ovarian oxytocin in cattle.
Reproduction in domestic animals = Zuchthygiene, , Volume: 46, Issue:1		2011
Side effects of phytoestrogens: a meta-analysis of randomized trials.
The American journal of medicine, , Volume: 122, Issue:10		2009
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study.
The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:12		2008
The phytoestrogenic isoflavones from Trifolium pratense L. (Red clover) protects human cortical neurons from glutamate toxicity.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 15, Issue:9		2008
A new database for food safety: EDID (Endocrine disrupting chemicals - Diet Interaction Database).
Annali dell'Istituto superiore di sanita, , Volume: 44, Issue:1		2008
Adverse effects of phytoestrogens on reproductive health: a report of three cases.
Complementary therapies in clinical practice, , Volume: 14, Issue:2		2008
Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer.
Menopause international, , Volume: 14, Issue:1		2008
Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation.
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Winter, Volume: 15, Issue:1		2008
Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women.
Menopause (New York, N.Y.), , Volume: 15, Issue:3
Soy isoflavones as safe functional ingredients.
Journal of medicinal food, , Volume: 10, Issue:4		2007
Safety of purified isoflavones in men with clinically localized prostate cancer.
Nutrition and cancer, , Volume: 59, Issue:2		2007
[The safety and tolerance of isoflavones (Soyfem) administration in postmenopausal women].
Ginekologia polska, , Volume: 78, Issue:5		2007
Challenges in the conduct of Thai herbal scientific study: efficacy and safety of phytoestrogen, pueraria mirifica (Kwao Keur Kao), phase I, in the alleviation of climacteric symptoms in perimenopausal women.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 90, Issue:7		2007
Genistein genotoxicity: critical considerations of in vitro exposure dose.
Toxicology and applied pharmacology, , Oct-01, Volume: 224, Issue:1		2007
A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals.
Nutrition reviews, , Volume: 65, Issue:6 Pt 1		2007
Endometrial safety assessment of a specific and standardized soy extract according to international guidelines.
Menopause (New York, N.Y.), , Volume: 14, Issue:6
Antigenotoxic effects of the phytoestrogen pelargonidin chloride and the polyphenol chlorogenic acid.
Molecular nutrition & food research, , Volume: 51, Issue:7		2007
Reproductive safety studies with genistein in rats.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 45, Issue:8		2007
First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055.
Menopause (New York, N.Y.), , Volume: 13, Issue:4
Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy.
Arzneimittel-Forschung, , Volume: 56, Issue:3		2006
Xenopus laevis is a potential alternative model animal species to study reproductive toxicity of phytoestrogens.
Aquatic toxicology (Amsterdam, Netherlands), , May-10, Volume: 77, Issue:3		2006
[Phytoestrogens: are they really safe?].
Folia medica Cracoviensia, , Volume: 45, Issue:1-2		2004
Acute, subchronic and chronic safety studies with genistein in rats.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 44, Issue:1		2006
Identification, design, synthesis, and pharmacological activity of (4-ethyl-piperazin-1-yl)-phenylmethanone derivatives with neuroprotective properties against beta-amyloid-induced toxicity.
Neuropharmacology, , Volume: 49, Issue:1		2005
Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers.
Advances in therapy, , Volume: 22, Issue:1
Genotoxicity of phytoestrogens.
Mutation research, , Jul-01, Volume: 574, Issue:1-2		2005
Subchronic and chronic safety studies with genistein in dogs.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 43, Issue:10		2005
Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.
Obstetrics and gynecology, , Volume: 105, Issue:5 Pt 1		2005
Phytoestrogenic isoflavones daidzein and genistein reduce glucose-toxicity-induced cardiac contractile dysfunction in ventricular myocytes.
Endocrine research, , Volume: 30, Issue:2		2004
The endocrine and reproductive system: adverse effects of hormonally active substances?
Pediatrics, , Volume: 113, Issue:4 Suppl		2004
Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 87, Issue:1		2004
Soy-based formulas and phyto-oestrogens: a safety profile.
Acta paediatrica (Oslo, Norway : 1992). Supplement, , Volume: 91, Issue:441		2003
Soy isoflavones: a safety review.
Nutrition reviews, , Volume: 61, Issue:1		2003
[Molecular mechanisms of environmental estrogens on reproductive and developmental toxicity].
Wei sheng yan jiu = Journal of hygiene research, , Volume: 31, Issue:2		2002
Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells.
Journal of neuroscience research, , Oct-01, Volume: 70, Issue:1		2002
The neuroprotective effects of phytoestrogens on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons.
The Journal of biological chemistry, , Feb-16, Volume: 276, Issue:7		2001
Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid.
Anticancer research, , Volume: 20, Issue:4
Herbal medicines, phytoestrogens and toxicity: risk:benefit considerations.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), , Volume: 217, Issue:3		1998
Directly toxic effects of plant chemicals which may occur in human and animal foods.
Natural toxins, , Volume: 3, Issue:4		1995

Long-term Use (21)

ArticleYear
Beneficial Role of Hydro-alcoholic Seed Extract of
Ethiopian journal of health sciences, , Volume: 28, Issue:6		2018
Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis.
Current drug targets, , Volume: 18, Issue:9		2017
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey.
BMC complementary and alternative medicine, , Jul-23, Volume: 14		2014
Management of postmenopausal osteoporosis and the prevention of fractures.
Panminerva medica, , Volume: 56, Issue:2		2014
Coumestrol and its metabolite in mares' plasma after ingestion of phytoestrogen-rich plants: potent endocrine disruptors inducing infertility.
Theriogenology, , Oct-01, Volume: 80, Issue:6		2013
Prevention strategies for prostate cancer.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology, , Volume: 64, Issue:4		2012
Dietary intake of phytoestrogen is associated with increased circulating endothelial progenitor cells in patients with cardiovascular disease.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, , Volume: 18, Issue:3		2011
A striking and frequent cause of premature thelarche in children: Foeniculum vulgare.
Journal of pediatric surgery, , Volume: 43, Issue:11		2008
Chronic administration of genistein improves aortic reactivity of streptozotocin-diabetic rats: mode of action.
Vascular pharmacology, , Volume: 49, Issue:1		2008
Effects of chronic genistein treatment in mammary gland, uterus, and vagina.
Environmental health perspectives, , Volume: 115 Suppl 1		2007
Soy isoflavones as safe functional ingredients.
Journal of medicinal food, , Volume: 10, Issue:4		2007
[The safety and tolerance of isoflavones (Soyfem) administration in postmenopausal women].
Ginekologia polska, , Volume: 78, Issue:5		2007
[Efficacy of standardized isoflavones extract (Soyfem) (52-104 mg/24h) in moderate and medium-severe climacteric syndrome].
Ginekologia polska, , Volume: 78, Issue:4		2007
A pilot study to examine a combination botanical for the treatment of menopausal symptoms.
Journal of alternative and complementary medicine (New York, N.Y.), , Volume: 11, Issue:3		2005
Long-term combined administration of quercetin and daidzein inhibits quercetin-induced suppression of glutathione antioxidant defenses.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 43, Issue:5		2005
[Soy isoflavones--a therapy for menopausal symptoms?].
Wiener medizinische Wochenschrift (1946), , Volume: 154, Issue:13-14		2004
Rat tail skin temperature regulation by estrogen, phytoestrogens and tamoxifen.
Maturitas, , Aug-20, Volume: 48, Issue:4		2004
Soy-based formulas and phyto-oestrogens: a safety profile.
Acta paediatrica (Oslo, Norway : 1992). Supplement, , Volume: 91, Issue:441		2003
Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials.
Annals of internal medicine, , Nov-19, Volume: 137, Issue:10		2002
Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 56, Issue:6		2002
Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995.
Human reproduction update, , Volume: 6, Issue:5

Pharmacokinetics (25)

ArticleYear
Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone.
Phytotherapy research : PTR, , Volume: 37, Issue:6		2023
A pilot pharmacokinetic study of miroestrol and deoxymiroestrol on rabbit sera using polyclonal antibody-based icELISA analysis.
Phytotherapy research : PTR, , Volume: 32, Issue:2		2018
Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women.
Menopause (New York, N.Y.), , Volume: 25, Issue:2		2018
The phytoestrogenic Cyclopia extract, SM6Met, increases median tumor free survival and reduces tumor mass and volume in chemically induced rat mammary gland carcinogenesis.
The Journal of steroid biochemistry and molecular biology, , Volume: 163		2016
Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats.
The British journal of nutrition, , Mar-14, Volume: 113, Issue:5		2015
Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops.
Molecular nutrition & food research, , Volume: 58, Issue:10		2014
[Pharmacokinetics of genistein in urine of healthy volunteers].
Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 48, Issue:9		2013
Pharmacokinetics and organ distribution of diarylheptanoid phytoestrogens from Curcuma comosa in rats.
Journal of natural medicines, , Volume: 66, Issue:3		2012
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the estrogen-like effect of ginsenoside Rb1 on neural 5-HT in ovariectomized mice.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Sep-18, Volume: 44, Issue:1-2		2011
Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor β-agonist being developed for the treatment of menopausal symptoms.
Menopause (New York, N.Y.), , Volume: 18, Issue:2		2011
The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers.
The American journal of clinical nutrition, , Volume: 90, Issue:4		2009
Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Molecular nutrition & food research, , Volume: 53 Suppl 1		2009
Determination and pharmacokinetic study of taxifolin in rabbit plasma by high-performance liquid chromatography.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 16, Issue:2-3		2009
Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens.
American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:1		2008
Molecular and pharmacodynamic properties of estrogenic extracts from the traditional Chinese medicinal herb, Epimedium.
Journal of ethnopharmacology, , Sep-05, Volume: 113, Issue:2		2007
Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
International journal of pharmaceutics, , Jun-07, Volume: 337, Issue:1-2		2007
Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women.
British journal of clinical pharmacology, , Volume: 62, Issue:3		2006
Physiologically-based pharmacokinetic modeling of genistein in rats, Part I: Model development.
Risk analysis : an official publication of the Society for Risk Analysis, , Volume: 26, Issue:2		2006
Metabolites and the pharmacokinetics of kobophenol A from Caragana sinica in rats.
Journal of ethnopharmacology, , Oct-03, Volume: 101, Issue:1-3		2005
Effects of dietary phytoestrogens on cardiac remodeling secondary to chronic volume overload in female rats.
Journal of applied physiology (Bethesda, Md. : 1985), , Volume: 99, Issue:4		2005
Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers.
Advances in therapy, , Volume: 22, Issue:1
Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia.
Nutrition and cancer, , Volume: 48, Issue:2		2004
Estrogens and phytoestrogens: brain plasticity of sexually dimorphic brain volumes.
The Journal of steroid biochemistry and molecular biology, , Volume: 85, Issue:2-5		2003
Altered sexually dimorphic nucleus of the preoptic area (SDN-POA) volume in adult Long-Evans rats by dietary soy phytoestrogens.
Brain research, , Sep-28, Volume: 914, Issue:1-2		2001
Differential effects of sex hormones and phytoestrogens on peak and steady state contractions in isolated rabbit detrusor.
The Journal of urology, , Volume: 162, Issue:5		1999

Bioavailability (95)

ArticleYear
A review on phytoestrogens: Current status and future direction.
Phytotherapy research : PTR, , Volume: 37, Issue:7		2023
Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone.
Phytotherapy research : PTR, , Volume: 37, Issue:6		2023
Understanding the Phytoestrogen Genistein Actions on Breast Cancer: Insights on Estrogen Receptor Equivalence, Pleiotropic Essence and Emerging Paradigms in Bioavailability Modulation.
Current topics in medicinal chemistry, , Volume: 23, Issue:15		2023
[no title available]
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, , Volume: 30, Issue:2		2022
Effects of Dietary Phytoestrogens on Hormones throughout a Human Lifespan: A Review.
Nutrients, , Aug-15, Volume: 12, Issue:8		2020
The influence of phytoestrogens on different physiological and pathological processes: An overview.
Phytotherapy research : PTR, , Volume: 35, Issue:1		2021
Fabrication of nanostructured mesoporous starch encapsulating soy-derived phytoestrogen (genistein) by well-tuned solvent exchange method.
International journal of biological macromolecules, , Sep-15, Volume: 159		2020
Enrichment of Polyglucosylated Isoflavones from Soybean Isoflavone Aglycones Using Optimized Amylosucrase Transglycosylation.
Molecules (Basel, Switzerland), , Jan-01, Volume: 25, Issue:1		2020
Phytoestrogens: Dietary Intake, Bioavailability, and Protective Mechanisms against Colorectal Neoproliferative Lesions.
Nutrients, , Jul-24, Volume: 11, Issue:8		2019
Increasing protective activity of genistein by loading into transfersomes: A new potential adjuvant in the oxidative stress-related neurodegenerative diseases?
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 52		2019
An Overview on Genistein and its Various Formulations.
Drug research, , Volume: 69, Issue:6		2019
Effectiveness of natural S-equol supplement for premenstrual symptoms: protocol of a randomised, double-blind, placebo-controlled trial.
BMJ open, , 07-18, Volume: 8, Issue:7		2018
Phytoestrogens: The current state of research emphasizing breast pathophysiology.
Phytotherapy research : PTR, , Volume: 32, Issue:9		2018
Absolute oral bioavailability and disposition kinetics of puerarin in female rats.
BMC pharmacology & toxicology, , 05-25, Volume: 19, Issue:1		2018
Phytoestrogens and mycoestrogens interacting with breast cancer proteins.
Steroids, , Volume: 134		2018
Evaluation of estrogenic activity of red clover (Trifolium pratense L.) sprouts cultivated under different conditions by content of isoflavones, calorimetric study and molecular modelling.
Food chemistry, , Apr-15, Volume: 245		2018
Resveratrol as MDR reversion molecule in breast cancer: An overview.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 103		2017
Effects of Vehicles and Enhancers on the Skin Permeation of Phytoestrogenic Diarylheptanoids from Curcuma comosa.
AAPS PharmSciTech, , Volume: 18, Issue:3		2017
An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health.
Critical reviews in food science and nutrition, , Apr-13, Volume: 57, Issue:6		2017
Phytoestrogen consumption and risk for cognitive decline and dementia: With consideration of thyroid status and other possible mediators.
The Journal of steroid biochemistry and molecular biology, , Volume: 160		2016
Bioactivation of Phytoestrogens: Intestinal Bacteria and Health.
Critical reviews in food science and nutrition, , Aug-17, Volume: 56, Issue:11		2016
Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats.
The British journal of nutrition, , Mar-14, Volume: 113, Issue:5		2015
Isoflavones in food supplements: chemical profile, label accordance and permeability study in Caco-2 cells.
Food & function, , Volume: 6, Issue:3		2015
Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Molecular nutrition & food research, , Volume: 58, Issue:11		2014
Plant coumestans: recent advances and future perspectives in cancer therapy.
Anti-cancer agents in medicinal chemistry, , Volume: 14, Issue:10		2014
S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.
Nutrition research (New York, N.Y.), , Volume: 34, Issue:2		2014
Orange juice and cancer chemoprevention.
Nutrition and cancer, , Volume: 65, Issue:7		2013
Beer and beer compounds: physiological effects on skin health.
Journal of the European Academy of Dermatology and Venereology : JEADV, , Volume: 28, Issue:2		2014
Increased in situ intestinal absorption of phytoestrogenic diarylheptanoids from Curcuma comosa in nanoemulsions.
AAPS PharmSciTech, , Volume: 14, Issue:3		2013
TPGS emulsified zein nanoparticles enhanced oral bioavailability of daidzin: in vitro characteristics and in vivo performance.
Molecular pharmaceutics, , May-06, Volume: 10, Issue:5		2013
Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Apr-15, Volume: 20, Issue:6		2013
Disposition of pharmacologically active dietary isoflavones in biological systems.
Current drug metabolism, , Volume: 14, Issue:4		2013
Isoflavones: estrogenic activity, biological effect and bioavailability.
European journal of drug metabolism and pharmacokinetics, , Volume: 38, Issue:1		2013
Ameliorative effect of daidzein: a caveolin-1 inhibitor in vascular endothelium dysfunction induced by ovariectomy.
Indian journal of experimental biology, , Volume: 50, Issue:1		2012
Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice.
Climacteric : the journal of the International Menopause Society, , Volume: 15, Issue:2		2012
Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation.
International journal of pharmaceutics, , Aug-30, Volume: 415, Issue:1-2		2011
Enhanced oral bioavailability of daidzein by self-microemulsifying drug delivery system.
Chemical & pharmaceutical bulletin, , Volume: 58, Issue:5		2010
Phytoestrogenic isoflavonoids in epidemiologic and clinical research.
Drug testing and analysis, , Volume: 1, Issue:1		2009
Development of a high-throughput LC/APCI-MS method for the determination of thirteen phytoestrogens including gut microbial metabolites in human urine and serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Apr-15, Volume: 878, Issue:13-14		2010
Phytoestrogens: science, evidence, and advice for breast cancer patients.
Journal of the Society for Integrative Oncology, ,Winter, Volume: 8, Issue:1		2010
Combination of genistin and fructooligosaccharides prevents bone loss in ovarian hormone deficiency.
Journal of medicinal food, , Volume: 13, Issue:2		2010
Controversies concerning the use of phytoestrogens in menopause management: bioavailability and metabolism.
Maturitas, , Volume: 65, Issue:4		2010
Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents.
The Journal of nutrition, , Volume: 139, Issue:12		2009
Increased NO bioavailability in aging male rats by genistein and exercise training: using 4, 5-diaminofluorescein diacetate.
Reproductive biology and endocrinology : RB&E, , Sep-07, Volume: 7		2009
7-Difluoromethyl-5,4'-dimethoxygenistein, a novel genistein derivative, has therapeutic effects on atherosclerosis in a rabbit model.
Journal of cardiovascular pharmacology, , Volume: 54, Issue:5		2009
The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers.
The American journal of clinical nutrition, , Volume: 90, Issue:4		2009
Influence of the "host-guest" interactions on the mobility of genistein/beta-cyclodextrin inclusion complex.
The journal of physical chemistry. B, , Aug-06, Volume: 113, Issue:31		2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
The Journal of clinical endocrinology and metabolism, , Volume: 94, Issue:10		2009
Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Molecular nutrition & food research, , Volume: 53 Suppl 1		2009
Food matrix and isoflavones bioavailability in early post menopausal women: a European clinical study.
Clinical interventions in aging, , Volume: 3, Issue:4		2008
Determination and pharmacokinetic study of taxifolin in rabbit plasma by high-performance liquid chromatography.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 16, Issue:2-3		2009
The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases.
Biomaterials, , Volume: 29, Issue:30		2008
Soy phytoestrogens: impact on postmenopausal bone loss and mechanisms of action.
Nutrition reviews, , Volume: 66, Issue:7		2008
[Isoflavones--an update on scientific data].
Medizinische Monatsschrift fur Pharmazeuten, , Volume: 31, Issue:1		2008
Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation.
Climacteric : the journal of the International Menopause Society, , Volume: 10, Issue:6		2007
Chemoprevention of prostate cancer through dietary agents: progress and promise.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, , Volume: 16, Issue:11		2007
Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects.
European journal of clinical nutrition, , Volume: 63, Issue:2		2009
Genistein genotoxicity: critical considerations of in vitro exposure dose.
Toxicology and applied pharmacology, , Oct-01, Volume: 224, Issue:1		2007
Higher bioavailability of isoflavones after a single ingestion of a soya-based supplement than a soya-based food in young healthy males.
The British journal of nutrition, , Volume: 99, Issue:2		2008
The bioavailability and disposition kinetics of genistein in cats.
Journal of veterinary pharmacology and therapeutics, , Volume: 30, Issue:4		2007
Plasma levels of genistein following a single dose of soy extract capsule in Indian women.
The Indian journal of medical research, , Volume: 125, Issue:4		2007
Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes.
Free radical biology & medicine, , Apr-01, Volume: 42, Issue:7		2007
Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, , Volume: 18, Issue:5		2007
Comparison of oral bioavailability of genistein and genistin in rats.
International journal of pharmaceutics, , Jun-07, Volume: 337, Issue:1-2		2007
Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
International journal of pharmaceutics, , Jun-07, Volume: 337, Issue:1-2		2007
Disposition of genistein in rainbow trout (Oncorhynchus mykiss) and siberian sturgeon (Acipenser baeri).
General and comparative endocrinology, , Jan-15, Volume: 150, Issue:2		2007
The effects of fructo-oligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats.
Menopause (New York, N.Y.), , Volume: 13, Issue:4
In vitro studies of intestinal permeability and hepatic and intestinal metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (Humulus lupulus L.).
Pharmaceutical research, , Volume: 23, Issue:5		2006
Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal Japanese women: a randomized placebo-controlled trial.
Metabolism: clinical and experimental, , Volume: 55, Issue:4		2006
Nutrition and primary prevention of breast cancer: foods, nutrients and breast cancer risk.
European journal of obstetrics, gynecology, and reproductive biology, , Dec-01, Volume: 123, Issue:2		2005
Repeated oral once daily intake of increasing doses of the novel synthetic genistein product Bonistein in healthy volunteers.
Planta medica, , Volume: 71, Issue:10		2005
Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 19, Issue:12		2005
Metabolites and the pharmacokinetics of kobophenol A from Caragana sinica in rats.
Journal of ethnopharmacology, , Oct-03, Volume: 101, Issue:1-3		2005
Activation of proestrogens from hops (Humulus lupulus L.) by intestinal microbiota; conversion of isoxanthohumol into 8-prenylnaringenin.
Journal of agricultural and food chemistry, , Aug-10, Volume: 53, Issue:16		2005
[Biologically-active phytochemicals in vegetable food].
Annali dell'Istituto superiore di sanita, , Volume: 41, Issue:1		2005
Bioavailability of isoflavone phytoestrogens in postmenopausal women consuming soya milk fermented with probiotic bifidobacteria.
The British journal of nutrition, , Volume: 93, Issue:6		2005
Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers.
Advances in therapy, , Volume: 22, Issue:1
Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibition of nitric oxide production and stimulation of endothelin-1 release in human umbilical vein endothelial cells.
Endocrine, , Volume: 25, Issue:3		2004
Health effects of phytoestrogens.
Forum of nutrition, , Issue:57		2005
The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide-synthase system in vitro.
British journal of pharmacology, , Volume: 144, Issue:3		2005
[Soy isoflavones--a therapy for menopausal symptoms?].
Wiener medizinische Wochenschrift (1946), , Volume: 154, Issue:13-14		2004
Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment.
The Journal of clinical endocrinology and metabolism, , Volume: 89, Issue:4		2004
Dietary lignins are precursors of mammalian lignans in rats.
The Journal of nutrition, , Volume: 134, Issue:1		2004
Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Oct-25, Volume: 796, Issue:1		2003
Bioavailability of phyto-oestrogens.
The British journal of nutrition, , Volume: 89 Suppl 1		2003
Bioactive substances of plant origin in food--impact on genomics.
Reproduction, nutrition, development, , Volume: 42, Issue:5
Composition, red blood cell uptake, and serum protein binding of phytoestrogens extracted from commercial kudzu-root and soy preparations.
Journal of medicinal food, ,Fall, Volume: 5, Issue:3		2002
Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements.
The Journal of nutrition, , Volume: 131, Issue:4 Suppl		2001
What strategies can women use to optimise bone health at this stage of life?
The Medical journal of Australia, , 11-06, Volume: 173, Issue:S4		2000
The therapeutic potential of phytoestrogens.
Expert opinion on investigational drugs, , Volume: 9, Issue:8		2000
[Chemoprevention of prostatic carcinoma].
Der Urologe. Ausg. A, , Volume: 39, Issue:4		2000
Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG).
Steroids, , Volume: 64, Issue:5		1999
The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens.
The Proceedings of the Nutrition Society, , Volume: 58, Issue:1		1999
Estrogen and progestin bioactivity of foods, herbs, and spices.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), , Volume: 217, Issue:3		1998
Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture.
Environmental health perspectives, , Volume: 105 Suppl 3		1997

Dosage (111)

ArticleYear
Understanding the Phytoestrogen Genistein Actions on Breast Cancer: Insights on Estrogen Receptor Equivalence, Pleiotropic Essence and Emerging Paradigms in Bioavailability Modulation.
Current topics in medicinal chemistry, , Volume: 23, Issue:15		2023
The association between urinary phytoestrogens and depressive symptoms.
International journal of food sciences and nutrition, , Volume: 73, Issue:5		2022
Phytoestrogens (Resveratrol and Equol) for Estrogen-Deficient Skin-Controversies/Misinformation versus Anti-Aging In Vitro and Clinical Evidence via Nutraceutical-Cosmetics.
International journal of molecular sciences, , Oct-18, Volume: 22, Issue:20		2021
Modulatory role of genistein on placenta and maternal bone minerals composition: further insight into its influence on pregnancy and foetal development.
Biologia futura, , Volume: 71, Issue:3		2020
Isoflavones alter male and female fertility in different development windows.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 140		2021
[no title available]
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, , Volume: 30, Issue:2		2022
Antineuroinflammation activity of n-butanol fraction of Marsilea crenata Presl. in microglia HMC3 cell line.
Journal of basic and clinical physiology and pharmacology, , Jan-22, Volume: 30, Issue:6		2020
Increasing protective activity of genistein by loading into transfersomes: A new potential adjuvant in the oxidative stress-related neurodegenerative diseases?
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 52		2019
Absolute oral bioavailability and disposition kinetics of puerarin in female rats.
BMC pharmacology & toxicology, , 05-25, Volume: 19, Issue:1		2018
The effects of the botanical estrogen, isoliquiritigenin on delayed spatial alternation.
Neurotoxicology and teratology, , Volume: 66
Preconception exposure to dietary levels of genistein affects female reproductive outcomes.
Reproductive toxicology (Elmsford, N.Y.), , Volume: 74		2017
In vitro-in silico-based analysis of the dose-dependent in vivo oestrogenicity of the soy phytoestrogen genistein in humans.
British journal of pharmacology, , Volume: 174, Issue:16		2017
Osteoinductive effects of glyceollins on adult mesenchymal stromal/stem cells from adipose tissue and bone marrow.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Apr-15, Volume: 27		2017
Phyto-oestrogens and colorectal cancer risk: a systematic review and dose-response meta-analysis of observational studies.
The British journal of nutrition, , Volume: 116, Issue:12		2016
Phytoestrogen consumption and risk for cognitive decline and dementia: With consideration of thyroid status and other possible mediators.
The Journal of steroid biochemistry and molecular biology, , Volume: 160		2016
In utero exposure to di-(2-ethylhexyl) phthalate induces testicular effects in neonatal rats that are antagonized by genistein cotreatment.
Biology of reproduction, , Volume: 93, Issue:4		2015
Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats.
The British journal of nutrition, , Mar-14, Volume: 113, Issue:5		2015
An exposure:activity profiling method for interpreting high-throughput screening data for estrogenic activity--proof of concept.
Regulatory toxicology and pharmacology : RTP, , Volume: 71, Issue:3		2015
Isoflavones in food supplements: chemical profile, label accordance and permeability study in Caco-2 cells.
Food & function, , Volume: 6, Issue:3		2015
Genistein modulation of streptozotocin diabetes in male B6C3F1 mice can be induced by diet.
Toxicology and applied pharmacology, , Nov-01, Volume: 280, Issue:3		2014
Disruption of rat testis development following combined in utero exposure to the phytoestrogen genistein and antiandrogenic plasticizer di-(2-ethylhexyl) phthalate.
Biology of reproduction, , Volume: 91, Issue:3		2014
The effects of isoflavones on androgens and glucocorticoids during puberty on male Wistar rats.
Reproduction in domestic animals = Zuchthygiene, , Volume: 49, Issue:4		2014
Genistein protects female nonobese diabetic mice from developing type 1 diabetes when fed a soy- and alfalfa-free diet.
Toxicologic pathology, , Volume: 43, Issue:3		2015
Phytoestrogens and cognitive function: a review.
Maturitas, , Volume: 77, Issue:3		2014
Genistein exposure during the early postnatal period favors the development of obesity in female, but not male rats.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 138, Issue:1		2014
Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus.
The British journal of nutrition, , Mar-14, Volume: 111, Issue:5		2014
A six-month randomized controlled trial of whole soy and isoflavones daidzein on body composition in equol-producing postmenopausal women with prehypertension.
Journal of obesity, , Volume: 2013		2013
Highly selective and sensitive determination of deoxymiroestrol using a polyclonal antibody-based enzyme-linked immunosorbent assay.
Talanta, , Sep-30, Volume: 114		2013
Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease.
Journal of Alzheimer's disease : JAD, , Volume: 37, Issue:2		2013
Impact of dose, frequency of administration, and equol production on efficacy of isoflavones for menopausal hot flashes: a pilot randomized trial.
Menopause (New York, N.Y.), , Volume: 20, Issue:9		2013
Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats.
Toxicology letters, , May-23, Volume: 219, Issue:2		2013
Clinical and ultrasonographic changes of the breast after use of soy isoflavones.
Asian Pacific journal of cancer prevention : APJCP, , Volume: 13, Issue:12		2012
Antiosteoporotic activity of echinacoside in ovariectomized rats.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Apr-15, Volume: 20, Issue:6		2013
Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Apr-15, Volume: 20, Issue:6		2013
Perturbation of male sexual behavior in mice (Mus musculus) within a discrete range of perinatal bisphenol-A doses in the context of a high- or low-phytoestrogen diet.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 55		2013
Pharmacokinetics and organ distribution of diarylheptanoid phytoestrogens from Curcuma comosa in rats.
Journal of natural medicines, , Volume: 66, Issue:3		2012
Antioxidant effect of a phytoestrogen equol on cultured muscle cells of embryonic broilers.
In vitro cellular & developmental biology. Animal, , Volume: 47, Issue:10		2011
Osteoprotective effect of Monascus-fermented dioscorea in ovariectomized rat model of postmenopausal osteoporosis.
Journal of agricultural and food chemistry, , Sep-14, Volume: 59, Issue:17		2011
Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis.
Chemico-biological interactions, , Jul-15, Volume: 192, Issue:3		2011
Neuromodulation by soy diets or equol: anti-depressive & anti-obesity-like influences, age- & hormone-dependent effects.
BMC neuroscience, , Mar-16, Volume: 12		2011
Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor β-agonist being developed for the treatment of menopausal symptoms.
Menopause (New York, N.Y.), , Volume: 18, Issue:2		2011
Increased sexual motivation in female rats treated with Humulus lupulus L. extract.
Journal of ethnopharmacology, , Mar-24, Volume: 134, Issue:2		2011
Estrogenic activities of sesame lignans and their metabolites on human breast cancer cells.
Journal of agricultural and food chemistry, , Jan-12, Volume: 59, Issue:1		2011
Circulating levels of genistein in the neonate, apart from dose and route, predict future adverse female reproductive outcomes.
Reproductive toxicology (Elmsford, N.Y.), , Volume: 31, Issue:3		2011
Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 48, Issue:12		2010
Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms.
Archives of gynecology and obstetrics, , Volume: 284, Issue:2		2011
Genistein aglycone: a dual mode of action anti-osteoporotic soy isoflavone rebalancing bone turnover towards bone formation.
Current medicinal chemistry, , Volume: 17, Issue:27		2010
Acute and chronic effects of oral genistein administration in neonatal mice.
Biology of reproduction, , Volume: 83, Issue:1		2010
Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II.
British journal of pharmacology, , Volume: 159, Issue:5		2010
[Research on phytoestrogenic effects and their mechanisms of Jiaoai tang and Shenqi Jiaoai tang].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 34, Issue:19		2009
The effects of α-zearalanol and estradiol benzoate on expression of c-myc, c-fos and epidermal growth factor receptor mRNAs in breast tissues implanted into nude mice.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, , Volume: 26, Issue:2		2010
Phytoestrogens as neuroprotectants.
Drugs of today (Barcelona, Spain : 1998), , Volume: 45, Issue:8		2009
Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents.
The Journal of nutrition, , Volume: 139, Issue:12		2009
Effects of phytoestrogen genistein on genioglossus function and oestrogen receptors expression in ovariectomized rats.
Archives of oral biology, , Volume: 54, Issue:11		2009
Inhibition of angiogenesis and inflammation by an extract of red clover (Trifolium pratense L.).
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 16, Issue:12		2009
Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Molecular nutrition & food research, , Volume: 53 Suppl 1		2009
Estrogenicity of food-associated estrogenic compounds in the fetuses of female transgenic mice upon oral and IP maternal exposure.
Reproductive toxicology (Elmsford, N.Y.), , Volume: 27, Issue:2		2009
Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause.
Recent patents on cardiovascular drug discovery, , Volume: 3, Issue:3		2008
Variance of estrogenic activity of the phytoestrogen-rich plant.
Maturitas, , Dec-20, Volume: 61, Issue:4		2008
Research on antioxidant effects and estrogenic effect of formononetin from Trifolium pratense (red clover).
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 16, Issue:4		2009
Sex steroid-induced inhibition of food intake in sea bass (Dicentrarchus labrax).
Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology, , Volume: 179, Issue:1		2009
Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).
National Toxicology Program technical report series, , Issue:539		2008
Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine.
The Journal of nutrition, , Volume: 138, Issue:7		2008
Determination of phytoestrogens in dietary supplements by LC-MS/MS.
Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, , Volume: 25, Issue:5		2008
[Synergistic antileukemic effect of phytoestrogens and chemotherapeutic drugs on leukemic cell lines in vitro].
Zhongguo shi yan xue ye xue za zhi, , Volume: 16, Issue:2		2008
Metabolic activation promotes estrogenic activity of the phytoestrogen-rich plant.
Maturitas, , Feb-20, Volume: 59, Issue:2		2008
The effects of phytoestrogens on fracture healing: experimental research in New Zealand white rabbits.
Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, , Volume: 14, Issue:1		2008
Determination of the estrogenic activity of wild phytoestrogen-rich Pueraria mirifica by MCF-7 proliferation assay.
The Journal of reproduction and development, , Volume: 54, Issue:1		2008
Chemoprevention of prostate cancer through dietary agents: progress and promise.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, , Volume: 16, Issue:11		2007
Pretreatment with phytoestrogen-rich plant decreases breast tumor incidence and exhibits lower profile of mammary ERalpha and ERbeta.
Maturitas, , Oct-20, Volume: 58, Issue:2		2007
[The safety and tolerance of isoflavones (Soyfem) administration in postmenopausal women].
Ginekologia polska, , Volume: 78, Issue:5		2007
Vitellogenin-inducing activities of natural, synthetic, and environmental estrogens in primary cultured Xenopus laevis hepatocytes.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, , Volume: 146, Issue:4		2007
Analysis of flavonoid phytoestrogens in botanical and ephedra-containing dietary supplements.
The Annals of pharmacotherapy, , Volume: 41, Issue:9		2007
Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.
Endocrine-related cancer, , Volume: 14, Issue:2		2007
[Efficacy of standardized isoflavones extract (Soyfem) (52-104 mg/24h) in moderate and medium-severe climacteric syndrome].
Ginekologia polska, , Volume: 78, Issue:4		2007
Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women.
The British journal of nutrition, , Volume: 98, Issue:5		2007
Inhibitory effects of soy isoflavones on cardiovascular collagen accumulation in rats.
Journal of nutritional science and vitaminology, , Volume: 53, Issue:1		2007
[Lignan: an important natural estrogen from plants].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 31, Issue:24		2006
Evaluation of the estrogenic activity of the wild Pueraria mirifica by vaginal cornification assay.
The Journal of reproduction and development, , Volume: 53, Issue:2		2007
Analysis of the interaction of phytoestrogens and synthetic chemicals: an in vitro/in vivo comparison.
Toxicology and applied pharmacology, , Feb-01, Volume: 218, Issue:3		2007
Urinary excretion of equol by postmenopausal women consuming soymilk fermented by probiotic bifidobacteria.
European journal of clinical nutrition, , Volume: 61, Issue:3		2007
Protective effect of daidzein against acute ethanol-induced lipid peroxidation in rat jejunum.
The Kobe journal of medical sciences, , Volume: 52, Issue:5		2006
Studies of the effects of neonatal exposure to genistein on the developing female reproductive system.
Journal of AOAC International, , Volume: 89, Issue:4
Using vaginal cytology to assess the estrogenic activity of phytoestrogen-rich herb.
Journal of ethnopharmacology, , Oct-11, Volume: 107, Issue:3		2006
Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice.
Carcinogenesis, , Volume: 27, Issue:4		2006
Genistein enhances N-nitrosomethylurea-induced rat mammary tumorigenesis.
Cancer letters, , Oct-08, Volume: 242, Issue:1		2006
Dose-response effects of phytoestrogens on the activity and expression of 3beta-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells.
The Journal of steroid biochemistry and molecular biology, , Volume: 96, Issue:3-4		2005
Bioavailability of isoflavone phytoestrogens in postmenopausal women consuming soya milk fermented with probiotic bifidobacteria.
The British journal of nutrition, , Volume: 93, Issue:6		2005
Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.
The Journal of steroid biochemistry and molecular biology, , Volume: 96, Issue:5		2005
Black cohosh: just another phytoestrogen?
Trends in endocrinology and metabolism: TEM, , Volume: 16, Issue:5		2005
Genotoxicity of phytoestrogens.
Mutation research, , Jul-01, Volume: 574, Issue:1-2		2005
Treatment options for menopausal hot flashes.
Cleveland Clinic journal of medicine, , Volume: 71, Issue:7		2004
Effects of nonylphenol and phytoestrogen-enriched diet on plasma vitellogenin, steroid hormone, hepatic cytochrome P450 1A, and glutathione-S-transferase values in goldfish (Carassius auratus).
Comparative medicine, , Volume: 54, Issue:1		2004
[Effects of daidzein on sperm quality, testis gain and testosterone in mice].
Zhonghua nan ke xue = National journal of andrology, , Volume: 9, Issue:8		2003
Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Oct-25, Volume: 796, Issue:1		2003
Potential therapeutic applications of some antinutritional plant secondary metabolites.
Journal of agricultural and food chemistry, , Sep-10, Volume: 51, Issue:19		2003
Prevention of osteopaenia by phyto-oestrogens: animal studies.
The British journal of nutrition, , Volume: 89 Suppl 1		2003
Measurement of intact sulfate and glucuronide phytoestrogen conjugates in human urine using isotope dilution liquid chromatography-tandem mass spectrometry with [13C(3)]isoflavone internal standards.
Analytical biochemistry, , Oct-01, Volume: 309, Issue:1		2002
Reproductive toxicology: current and future directions.
Biochemical pharmacology, , Dec-15, Volume: 62, Issue:12		2001
Estrogen and related compounds: biphasic dose responses.
Critical reviews in toxicology, , Volume: 31, Issue:4-5		2001

Interactions (8)

ArticleYear
Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones.
Archives of toxicology, , Volume: 96, Issue:12		2022
Soy protein supplementation is not androgenic or estrogenic in college-aged men when combined with resistance exercise training.
Scientific reports, , 07-24, Volume: 8, Issue:1		2018
[Effects of phytoestrogen, genistein combined with calcium and vitamin D3 on preventing osteoporosis in ovariectomized mice].
Wei sheng yan jiu = Journal of hygiene research, , Volume: 40, Issue:5		2011
Effect of exercise training combined with phytoestrogens on adipokines and C-reactive protein in postmenopausal women: a randomized trial.
Metabolism: clinical and experimental, , Volume: 61, Issue:2		2012
Effect of exercise combined with phytoestrogens on quality of life in postmenopausal women.
Climacteric : the journal of the International Menopause Society, , Volume: 14, Issue:5		2011
Effect of estrogenic compounds (estrogen or phytoestrogens) combined with exercise on bone and muscle mass in older individuals.
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, , Volume: 33, Issue:1		2008
Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model.
Bone, , Volume: 39, Issue:1		2006
Dietary supplement-drug interactions.
Journal of the American Medical Women's Association (1972), ,Fall, Volume: 54, Issue:4		1999

Natural Sources (3)

ArticleYear
Developmental exposure to phytoestrogens found in soy: New findings and clinical implications.
Biochemical pharmacology, , Volume: 195		2022
Polyphenols from Erythrina crista-galli: Structures, Molecular Docking and Phytoestrogenic Activity.
Molecules (Basel, Switzerland), , Jun-03, Volume: 21, Issue:6		2016
Soy isoflavones--benefits and risks from nature's selective estrogen receptor modulators (SERMs).
Journal of the American College of Nutrition, , Volume: 20, Issue:5 Suppl		2001